DEVICE FOR DETECTING A BACTERIA OF INTEREST

A lateral flow chromatography strip using bacteriophages specific to Staphylococcus aureus allows breeders to rapidly and cost-effectively detect the bacteria in the field, addressing the limitations of existing methods and enabling timely intervention in dairy herd management.

FR3110703B1Active Publication Date: 2024-11-29VETOPHAGE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
FR2020005352
Authority / Receiving Office
FR · FR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2020-05-20
Publication Date
2024-11-29
Estimated Expiration
2040-05-20

AI Technical Summary

Technical Problem

Current methods for detecting Staphylococcus aureus in dairy herds are not rapid, practical, or cost-effective for breeders to use in the field, and existing techniques like PCR require laboratory analysis and are prone to false positives.

Method used

A lateral flow chromatography strip using bacteriophages specific to Staphylococcus aureus or their proteins for rapid detection, allowing breeders to identify the bacteria directly in the field without large equipment.

Benefits of technology

The method provides a simple, rapid, and inexpensive way to detect Staphylococcus aureus, reducing the need for laboratory analysis and minimizing false positives, enabling timely intervention in dairy herd management.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000048_0000
    Figure 00000048_0000
  • Figure 00000049_0000
    Figure 00000049_0000
  • Figure 00000049_0001
    Figure 00000049_0001
Patent Text Reader

Abstract

The present invention relates to a lateral flow chromatography strip for the detection of bacteria of interest in a sample, the strip comprising at least one portion that includes at least one bacteriophage specific to the bacterium of interest and / or at least one protein from at least one bacteriophage specific to the bacterium of interest. The present invention also relates to a method and a kit for detecting a bacterium of interest in a sample with such a strip. [Fig. **]
Need to check novelty before this filing date? Find Prior Art

Description

Title of the invention: DEVICE FOR DETECTING A BACTERIUM OF INTEREST Technical field

[0001] The present invention relates to a device for detecting the presence of a bacterium of interest in a sample using a phage specific to the bacterium of interest or a protein of a phage specific to the bacterium of interest. Context of the invention

[0002] Staphylococcus aureus is one of the most common bacterial species encountered in human and veterinary pathology (Reinoso et al., 2004).

[0003] In cattle farming, this bacterium is the main cause of mastitis, a contagious disease in dairy herds. Indeed, after milking, the teats remain open and pathogenic germs, including S. aureus, can penetrate. The bacterium can colonize and infect the cow's udders, which leads to a sharp drop in milk production. The drop in milk production due to clinical mastitis is on average 5% over a lactation, or 400 liters of milk for a lactation of 8,000 liters (www.web-agri.fr / conduite-elevage / sante-animale / article / l-impact-economique-atteint-230-vache-an-l 184-97330.html).

[0004] Since Staphylococcus aureus is often resistant to antibiotics, it is very difficult to eradicate it (Foster Timothy J., 2017).

[0005] To combat the occurrence of mastitis due to Staphylococcus aureus, one way would be to implement preventive treatments to reduce the number of infected cows, by limiting any contact between sick cows and healthy cows or by avoiding lesions of the teats.

[0006] It is therefore essential to develop rapid solutions to be able to detect the presence of this bacterium in the breeding environment, in particular in raw milk from cows, in order to prevent and / or treat bacterial infections, in particular by the use of antibiotics appropriate to the pathogenic bacterium detected. However, to date, no detection method is fully satisfactory.

[0007] Mastitis diagnostic devices on the market are mainly based on the screening of somatic cells found in milk. However, this method does not allow the identification of the bacteria responsible for the infection. On the other hand, the latter may constitute a trace of a more or less old infection and therefore constitute a non-specific indicator of an ongoing infection. This therefore leads breeders to use antibiotic therapies massively and untargeted.

[0008] Other methods of detecting bacteria can be used such as the polymerase chain reaction (PCR) or the culture method. However, these require sending the samples to the laboratory and therefore the intervention of qualified people to implement the detection method and to analyze the results.

[0009] In addition, using the culture method requires an incubation time of 24 to 48 hours, which represents too long a wait for results, given the challenges of the sector. The molecular biology approach has made it possible to develop specific methods such as PCR and quantitative PCR. However, although faster and more specific, PCR methods are much more expensive. In addition, the PCR technique only detects the presence of bacterial DNA and not the presence of viable bacteria, which can lead to the detection of false positives (dead bacteria already taken care of by the cow's immune system).

[0010] Thus, existing methods do not meet the needs of breeders because they cannot be implemented by the breeders themselves. In addition, they are quite restrictive because they require the sample to be taken under aseptic conditions and sent quickly to the laboratory under refrigerated conditions. Methods with lower specificity are therefore relatively long and unsuitable for the need to quickly implement treatment / prevention measures in the face of the contagious nature of the bacteria responsible for bovine mastitis, of which S. aureus is one of the primary causes. PCR methods, for their part, represent a high analysis cost and are therefore not suited to the need to diagnose a large number of cows.

[0011] The major challenge is to have a simple, rapid, practical (without large equipment), and inexpensive method so that breeders can use it themselves in the field to detect the presence of S. aureus in their farms.

[0012] Furthermore, such a method for detecting S. aureus bacteria could also be applied in different fields such as, for example, food safety, water control or human health. Summary of the invention

[0013] A first aspect of the invention relates to a strip for detecting a bacterium of interest by lateral flow chromatography comprising a part which comprises at least one bacteriophage specific to the bacterium of interest and / or at least one protein of at least one bacteriophage specific to the bacterium of interest.

[0014] A second aspect of the invention relates to a method for detecting a bacterium of interest in a sample.

[0015] A third aspect of the invention relates to a kit for detecting a bacterium of interest in a sample.

[0016] A fourth aspect of the invention relates to the use of a bacteriophage specific for a bacterium of interest or a protein thereof in a lateral flow chromatography device for detecting said bacterium of interest in a sample. Statement of the invention

[0017] For the purposes of the present application, "lateral flow chromatography" (lateral flow assay, LFA) means a chromatography device in which a liquid sample migrates by capillarity in a flow directed through a strip. LFA is known from the prior art and has in particular been described for the immunological detection of an analyte of interest in a liquid sample, using a primary antibody and a secondary antibody (EP1086372B1; US ​​8,399,261 B2; WO 2017 / 072078; Nanerjee and Jaiswal, 2018).

[0018] For the purposes of the present application, "at least one" means one, two, three, four, five and the following.

[0019] For the purposes of the present application, a “bacteriophage specific to a bacterium of interest” is a bacteriophage capable of binding specifically to this bacterium. This specificity can be determined by the spot method described in the present application. A bacteriophage is specific to a bacterium if a lysis plaque is observed around a spot containing said bacteriophage, deposited on a Petri dish covered with a culture of said bacterium in exponential phase, after 18 hours of incubation at a temperature suitable for the bacterium.

[0020] By "at least one specific bacteriophage" is meant that it may be one, two, three, four or five bacteriophages specific to a bacterium of interest, or more. For the purposes of the present invention, said at least one specific bacteriophage is in particular at least one bacteriophage specific to S. aureus. More particularly, said at least one bacteriophage specific to S. aureus is chosen from the bacteriophages specific to S. aureus deposited at the National Collection of Microorganism Cultures (CNCM) under the numbers CNCM 1-5408, CNCM 1-5409, CNCM 1-5410, CNCM 1-5491 and CNCM 1-5492. In particular, it may be two bacteriophages specific to S.aureus such as bacteriophage CNCM 1-5408 and bacteriophage CNCM 1-5409, bacteriophage CNCM 1-5409 and bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5408 and bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5408 and bacteriophage CNCM 1-5491, bacteriophage CNCM 1-5409 and bacteriophage CNCM 1-5491, bacteriophage CNCM 1-5410 and bacteriophage CNCM 1-5491, bacteriophage CNCM 1-5408 and bacteriophage CNCM 1-5492, . bacteriophage CNCM 1-5409 and bacteriophage CNCM 1-5492, bacteriophage CNCM 1-5410 and bacteriophage CNCM 1-5492 or bacteriophage CNCM 1-5491 and bacteriophage CNCM 1-5492. In particular, these may be three bacteriophages specific to S.aureus such as bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409 and CNCM 1-5410, bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5491 and CNCM 1-5492, bacteriophages deposited under numbers CNCM 1-5409, CNCM 1-5491 and CNCM 1-5492, bacteriophages deposited under numbers CNCM 1-5410, CNCM 1-5491 and CNCM 1-5492, bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409 and CNCM 1-5491, bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5410 and CNCM 1-5491, the bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409 and CNCM 1-5492, the bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5410 and CNCM 1-5492, the bacteriophages deposited under numbers CNCM 1-5409, CNCM I-5410 and CNCM 1-5491, the bacteriophages deposited under numbers CNCM 1-5409, CNCM 1-5410 and CNCM 1-5492. In particular, these may be four bacteriophages specific to S.aureus such as bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409, CNCM 1-5410 and CNCM 1-5491, bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409, CNCM 1-5410 and CNCM 1-5492, bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409, CNCM 1-5491 and CNCM 1-5492, bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5410, CNCM 1-5491 and CNCM 1-5492, bacteriophages deposited under numbers CNCM 1-5410, CNCM 1-5409, CNCM 1-5491 and CNCM 1-5492. In particular, these may be five bacteriophages specific to S. aureus such as the bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409, CNCM 1-5410, CNCM 1-5491 and CNCM 1-5492.

[0021] By "at least one protein of at least one bacteriophage" is meant that it may be a protein of a bacteriophage, several proteins (for example two or three) of the same bacteriophage, a protein of several bacteriophages (for example two or three), or several proteins of several different bacteriophages. The definition given above for "at least one specific bacteriophage" is integrated into the definition of "at least one protein of at least one bacteriophage". In other words, in particular, said at least one protein of at least one bacteriophage specific to a bacterium of interest may be at least one protein of at least one bacteriophage specific to S. aureus. More particularly, it may be at least one protein of at least one bacteriophage specific to S. aureus chosen from the bacteriophages specific to S.aureus déposés à la Collection Nationale de Cultures de Microorganismes (CNCM) sous les numéros CNCM 1-5408, CNCM I-5409, CNCM 1-5410, CNCM 1-5491 et CNCM 1-5492. Par exemple, il peut s'agir d'au . at least one protein of bacteriophage CNCM 1-5408 and at least one protein of bacteriophage CNCM 1-5409, at least one protein of bacteriophage CNCM I-5409 and at least one protein of bacteriophage CNCM 1-5410, at least one protein of bacteriophage CNCM 1-5408 and at least one protein of bacteriophage CNCM 1-5410, at least one protein of bacteriophage CNCM 1-5408 and at least one protein of bacteriophage CNCM 1-5491, at least one protein of bacteriophage CNCM 1-5409 and at least one protein of bacteriophage CNCM 1-5491, at least one protein of bacteriophage CNCM 1-5410 and at least one protein of bacteriophage CNCM 1-5491, at least one protein of bacteriophage CNCM I-5408 and at least one protein of bacteriophage CNCM 1-5492, at least one protein of bacteriophage CNCM 1-5409 and at least one protein of bacteriophage CNCM 1-5492, at least one protein of bacteriophage CNCM 1-5410 and at least one protein of bacteriophage CNCM 1-5492,of at least one protein of the bacteriophage CNCM 1-5491 and at least one protein of the bacteriophage CNCM 1-5492. In particular, it may be at least one protein of the bacteriophage CNCM 1-5408, at least one protein of the bacteriophage CNCM 1-5409 and at least one protein of the bacteriophage CNCM 1-5410; of at least one protein of the bacteriophage CNCM 1-5408, at least one protein of the bacteriophage CNCM 1-5491 and at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of the bacteriophage CNCM 1-5409, at least one protein of the bacteriophage CNCM 1-5491 and at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of the bacteriophage CNCM 1-5410, of at least one protein of the bacteriophage CNCM 1-5491 and of at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of the bacteriophage CNCM 1-5408, of at least one protein of the bacteriophage CNCM 1-5409 and of at least one protein of the bacteriophage CNCM 1-5491; of at least one protein of the bacteriophage CNCM 1-5408,of at least one protein of the bacteriophage CNCM 1-5410 and at least one protein of the bacteriophage CNCM 1-5491; of at least one protein of the bacteriophage CNCM 1-5408, of at least one protein of the bacteriophage CNCM 1-5409 and of at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of the bacteriophage CNCM 1-5408, of at least one protein of the bacteriophage CNCM 1-5410 and of at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of the bacteriophage CNCM 1-5409, of at least one protein of the bacteriophage CNCM 1-5410 and of at least one protein of the bacteriophage CNCM 1-5491; of at least one protein of the bacteriophage CNCM 1-5409, of at least one protein of the bacteriophage CNCM 1-5410 and of at least one protein of the bacteriophage CNCM 1-5492. In particular, it is at least one protein of the bacteriophage CNCM 1-5408, of at least one protein of the bacteriophage CNCM 1-5409,of at least one protein of the bacteriophage CNCM 1-5410 and of at least one protein of the bacteriophage CNCM 1-5491; of at least one protein of the bacteriophage CNCM I-, 5408, at least one protein of the bacteriophage CNCM 1-5409, at least one protein of the bacteriophage CNCM 1-5410 and at least one protein of the bacteriophage CNCM 1-5492; at least one protein of the bacteriophage CNCM 1-5408, at least one protein of the bacteriophage CNCM 1-5409, at least one protein of the bacteriophage CNCM 1-5491 and at least one protein of the bacteriophage CNCM 1-5492; at least one protein of the bacteriophage CNCM 1-5408, at least one protein of the bacteriophage CNCM 1-5410, at least one protein of the bacteriophage CNCM I-5491 and at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of bacteriophage CNCM 1-5410, of at least one protein of bacteriophage CNCM 1-5409, of at least one protein of bacteriophage CNCM 1-5491 and of at least one protein of bacteriophage CNCM 1-5492.In particular, it is at least one protein of bacteriophage CNCM 1-5408, at least one protein of bacteriophage CNCM 1-5409, at least one protein of bacteriophage CNCM 1-5410, at least one protein of bacteriophage CNCM 1-5491 and at least one protein of bacteriophage CNCM 1-5492.

[0022] In particular, said at least one protein of at least one bacteriophage specific to a bacterium of interest or said at least one protein of at least one bacteriophage specific to S. aureus is a binding protein (RBP, receptor binding protein). More particularly, it is at least one RBP protein of at least one bacteriophage specific to S. aureus chosen from the bacteriophages specific to S. aureus deposited in the National Collection of Microorganism Cultures (CNCM) under the numbers CNCM 1-5408, CNCM 1-5409, CNCM 1-5410, CNCM 1-5491 and CNCM 1-5492.

[0023] Even more particularly, the RBP protein of bacteriophage CNCM 1-5408 is the protein SEQ ID NO: 1; the RBP protein of bacteriophage CNCM 1-5409 is the protein SEQ ID NO: 2; the RBP protein of bacteriophage CNCM 1-5410 is the protein SEQ ID NO: 3.

[0024] The specificity of recognition of a phage protein for a bacterium can be established by placing the bacterium and magnetic beads coated with a phage protein in the presence of the bacterium, followed by recovery of the magnetic beads using a magnetic support, then after resuspension in a buffer, spreading on a culture medium (in particular a specific agar). After 24 to 48 hours at a temperature appropriate for the bacterium, a significant difference between the count of bacterial colonies on the culture medium where the magnetic beads coated with the protein have been spread and the count of bacterial colonies on a culture medium where magnetic beads incubated with the bacterium but not coated with the protein, means that the phage protein is capable of binding to the bacterium.

[0025] In the present application, the terms “bacteriophage” and “phage” designate the same entity, they are used interchangeably and are interchangeable.

[0026] In the present application, the expressions “antibody directed against X” and “anti-X antibodies” are equivalent and interchangeable.

[0027] In the present application, the expressions “X conjugated to Y” and Y conjugated to X” are equivalent. The term “labeled” means “conjugated to a marker”.

[0028] A first aspect of the invention relates to a lateral flow chromatography strip for detecting a bacterium of interest in a sample.

[0029] The embodiments of the lateral flow chromatography strip described below are described before use of said strip, i.e. before contact with the sample to be analyzed.

[0030] Thus, the present invention also relates to a lateral flow chromatography strip for detecting a bacterium of interest, in particular S. aureus, in a sample, comprising at least one part which comprises at least one bacteriophage specific for the bacterium of interest and / or at least one protein of a bacteriophage specific for the bacterium of interest.

[0031] In a particular embodiment, said lateral flow chromatography strip comprises in order at least: - a contact part comprising a contact area with the sample; - a detection part comprising a detection zone of the bacterium of interest which comprises at least one bacteriophage specific to said bacterium of interest and / or at least one protein of at least one bacteriophage specific to said bacterium of interest, - an absorbent part.

[0032] The contact portion (sample pad) comprises a contact area intended to be brought into contact with the sample. Its function is to distribute the sample uniformly so that the migration of the sample by capillarity to the following parts is smooth, continuous and homogeneous. The contact portion and the contact area are a capillary matrix. For example, the contact portion and the contact area are made of cellulose or glass fibers.

[0033] The detection part (detection pad) comprises a detection zone where the bacteria of interest, if present in the analyzed sample, is captured on the strip thanks to a specific ligand thereof which is immobilized there. The role of the detection part is therefore to provide a good support and a good bond for the immobilization of the specific ligands, while limiting non-specific adsorptions. For example, the detection part and the detection zone are a nitrocellulose membrane.

[0034] In particular, said at least one bacteriophage protein specific to the bacterium of interest is an RBP protein.

[0035] The absorbent part (absorbent pad) has an absorption role. It thus contributes to maintain the flow rate through the strip and allow excess sample and reagents to be collected, thus preventing sample backflow. For example, the absorbent part is made of cotton, cotton mixed with glass fibers, cellulose or nitrocellulose.

[0036] For the purposes of the present application, "in order" means the order in which the different parts which make up the strip will be crossed by the flow containing the sample, but this term does not mean that these parts are necessarily contiguous.

[0037] In a particular embodiment, one of the ends of the contact portion is superimposed with one of the ends of the portion downstream thereof to form a first superposition zone, one of the ends of the detection portion is superimposed with one of the ends of the portion upstream thereof to form a second superposition zone and the other end of the detection portion is superimposed with one of the ends of the portion downstream thereof to form a third superposition zone, and one of the ends of the absorbent portion is superimposed with one of the ends of the portion downstream thereof to form a fourth superposition zone. In particular, the first, second and third superposition zones are distinct from each other. In particular, the contact zone is distinct from the first superposition zone.In particular, the detection zone is distinct from the second and third overlapping zones.

[0038] In a particular embodiment, one of the ends of the detection part is superimposed with one of the ends of the contact part and the other end of the detection part is superimposed with one of the ends of the absorbent part.

[0039] In a more particular embodiment, one of the ends of the detection portion is superimposed with one of the ends of the contact portion to form a first superposition zone, and the other end of the detection portion is superimposed with one of the ends of the absorbent portion to form a second superposition zone. In particular, the first, second and third superposition zones are separated from each other. In particular, the contact zone is distinct from the first superposition zone. In particular, the detection zone is distinct from the first and second superposition zones.

[0040] In a particular embodiment, the detection zone is a line transverse to the strip, thus forming a detection line or test line.

[0041] Optionally, the strip comprises a system for controlling the migration of the sample from the contact part to the detection part. Thus, optionally, the detection part comprises a control zone, preferably downstream of the detection zone. This control zone is distinct from the detection zone. In particular, it is also distinct from the superposition zones. In particular, the control zone is a line across the strip, forming a control line. The control zone comprises a ligand specific for an analyte other than the bacterium of interest. The analyte is conjugated to a label. Optionally, the label-conjugated analyte is deposited on a portion of the strip upstream of the detection portion and / or is added beforehand to the sample. For example, the labeled analyte is a label-conjugated primary antibody and the ligand on the control zone is a secondary antibody directed against the label-conjugated primary antibody.

[0042] In a more particular embodiment, the present invention relates to a lateral flow chromatography strip for detecting S. aureus in a sample, comprising in order at least: - a contact part comprising a contact area with the sample; - a detection part comprising an S. aureus detection zone which comprises at least one S. aureus-specific bacteriophage and / or at least one protein of at least one S. aureus-specific bacteriophage, in particular said at least one protein is an RBP, - an absorbent part.

[0043] In particular, the detection zone comprises a CNCM 1-5408 phage, a CNCM 1-5409 phage, a CNCM 1-5410 phage, a CNCM 1-5491 phage and / or a CNCM 1-5492 phage. In particular, the detection zone comprises a CNCM 1-5408 phage, a CNCM 1-5409 phage and a CNCM 1-5410 phage.

[0044] In particular, the detection zone comprises at least one protein of phage CNCM 1-5408, at least one protein of phage CNCM 1-5409, at least one protein of phage CNCM 1-5410, at least one protein of phage CNCM 1-5491 and / or at least one protein of phage CNCM 1-5492. In particular, the detection zone comprises at least one protein of phage CNCM 1-5408, at least one protein of phage CNCM 1-5409 and at least one protein of phage CNCM 1-5410.

[0045] In a particular embodiment, said strip further comprises, between the contact portion and the detection portion, a marking portion which comprises a marking area.

[0046] The marking part (conjugal pad) comprises a marking area where the bacteria are marked with a marker when the sample flow to be analyzed passes through it. Their role is to hold the marker until the strip is used and to release the marker when there is recognition between the marker and a bacterium, as the sample flow passes through. For example, the marking part and the marking area are made of glass fibers, cellulose or polyesters.

[0047] Thus, in a particular embodiment, the present invention relates to a lateral flow chromatography strip for detecting a bacterium of interest in a sample, comprising in order at least: - a contact part comprising a contact area with the sample; - a marking portion comprising a marking area which comprises a marker; - a detection part comprising a detection zone of the bacterium of interest which comprises at least one bacteriophage specific to said bacterium of interest and / or at least one protein of at least one bacteriophage specific to said bacterium of interest, - an absorbent part.

[0048] The marker may be any marker capable of marking a bacterium. Bacterial markers are well known to those skilled in the art.

[0049] The term "marker" includes both unconjugated and conjugated markers.

[0050] For the purposes of the present application, an unconjugated marker is a free marker, i.e. it is not bound to a ligand to mark the bacteria. These are, for example, fluorescent dyes. Fluorescent dyes capable of marking bacteria are well known to those skilled in the art, such as DAPI (4',6-diamidino-2-phenylindole) or SYTO9 as examples.

[0051] A conjugated label may be, for example: a gold nanoparticle (AuNP) or colloidal gold, a carbon nanoparticle or colloidal carbon, a colored latex bead, a magnetic particle, a quantum dot, an upconverting phosphor (UCP), a luminescent molecule including fluorescent molecules (fluorophores) and phosphorescent molecules, a dye, a liposome, or an enzyme such as horseradish peroxidase that catalyzes the conversion of chromogenic substrates into colored compounds, or that produces light from chemiluminescent substrates. These conjugated labels are known from the prior art (Sajid et al., 2015).

[0052] In particular, it is a gold nanoparticle (AuNP). By "gold nanoparticle" we mean that it can be a gold nanosphere or a gold nanorod. The aggregation of the gold nanoparticles leads to the appearance of a color detectable in the visible, which varies depending on the size of the nanoparticles.

[0053] For the purposes of the present application, a conjugated marker means that the marker is linked to a ligand to label the bacterium. In particular, the conjugated marker is a marker conjugated to at least one ligand specific to the bacterium of interest. By "conjugated to at least one specific ligand" is meant that a marker can be conjugated to one specific ligand or to several different specific ligands.

[0054] Unless otherwise stated, within the meaning of the present invention, said at least one ligand specific for the bacterium of interest may be at least one antibody directed against the bacterium of interest, at least one aptamer specific for the bacterium of interest, at least a bacteriophage specific for the bacterium of interest, at least one protein of at least one bacteriophage specific for the bacterium of interest, at least one bacteriophage specific for the bacterium of interest coupled to an antibody directed against the bacterium of interest, at least one protein of a bacteriophage specific for the bacterium of interest coupled to an antibody directed against the bacterium of interest. In particular, the bacterium of interest is S. aureus and these specific ligands read as ligands specific for S. aureus or directed against S. aureus. In particular, when the ligand is specific for S. aureus, said at least one bacteriophage specific for S.aureus is a bacteriophage CNCM 1-5408, a bacteriophage CNCM 1-5409, a bacteriophage CNCM 1-5410, a bacteriophage CNCM 1-5491 and / or a bacteriophage CNCM I-5492; and said at least one protein of at least one bacteriophage, in particular an RBP, is at least one protein of bacteriophage CNCM 1-5408, at least one protein of bacteriophage CNCM 1-5409, at least one protein of bacteriophage CNCM 1-5410, at least one protein of bacteriophage CNCM 1-5491 and / or at least one protein of bacteriophage CNCM 1-5492. More particularly, said at least . a protein of phage CNCM 1-5408 is the protein SEQ ID NO: 1, said at least a protein of phage CNCM 1-5409 is the protein SEQ ID NO:2, said at least a protein of phage CNCM 1-5410 is protein SEQ ID NO:3.

[0055] In particular, said at least one protein of at least one bacteriophage specific to the bacterium of interest is an RBP protein.

[0056] Thus, the marker conjugated to a ligand specific to the bacterium of interest, in particular S. aureus, may be a marker conjugated to an antibody directed against the bacterium of interest, a marker conjugated to an aptamer specific to the bacterium of interest, a marker conjugated to a phage specific to the bacterium of interest, a marker conjugated to a protein of a phage specific to the bacterium of interest, a marker conjugated to a phage specific to the bacterium of interest coupled to an antibody directed against the bacterium of interest, a marker conjugated to an antibody directed against the bacterium of interest coupled to a phage specific to the bacterium of interest or a marker conjugated to a protein of a phage specific to the bacterium of interest coupled to an antibody directed against the bacterium of interest.

[0057] In a more particular embodiment, the present invention relates to a lateral flow chromatography strip for detecting S. aureus in a sample, comprising in order at least: - a contact part comprising a contact area with the sample; - a labeling portion comprising a labeling area which comprises a label conjugated to at least one ligand specific for S. aureus, in particular a na- gold particle conjugated to at least one ligand specific to S. aureus; - a detection part comprising an S. aureus detection zone which comprises at least one S. aureus-specific bacteriophage and / or a protein of at least one S. aureus-specific bacteriophage, in particular an RBP protein, - an absorbent part.

[0058] In particular, the marking zone comprises a marker conjugated to an anti-S. aureus antibody or a marker conjugated to an aptamer specific to S. aureus, more particularly a gold nanoparticle conjugated to an anti-S. aureus antibody or a gold nanoparticle conjugated to an aptamer specific to S. aureus.

[0059] In particular, the marking zone comprises a marker conjugated to at least one bacteriophage specific for S. aureus. In particular, it comprises a marker conjugated to phage CNCM 1-5408, a marker conjugated to phage CNCM 1-5409, a marker conjugated to phage CNCM 1-5410, a marker conjugated to phage CNCM 1-5491 and / or a marker conjugated to phage CNCM 1-5492. In particular, it comprises a marker conjugated to phage CNCM 1-5408, a marker conjugated to phage CNCM 1-5409 and a marker conjugated to phage CNCM 1-5410. More particularly, said marker conjugated to these phages is a gold nanoparticle.

[0060] In particular, the marking area comprises a marker conjugated to at least one protein of at least one bacteriophage specific for S. aureus. In particular, said at least one protein is an RBP. In particular, the marking area comprises a marker conjugated to at least one protein of phage CNCM 1-5408, a marker conjugated to at least one protein of phage CNCM 1-5409, a marker conjugated to at least one protein of phage CNCM 1-5410, a marker conjugated to at least one protein of phage CNCM 1-5491 and / or a marker conjugated to at least one protein of phage CNCM 1-5492. In particular, it comprises a marker conjugated to at least one protein of the phage CNCM 1-5408, a marker conjugated to at least one protein of the phage CNCM 1-5409, and a marker conjugated to at least one protein of the phage CNCM 1-5410.In particular, in these examples of conjugation of the marker, said at least one protein of the phage CNCM 1-5408 is the protein SEQ ID NO: 1, said at least one protein of the phage CNCM 1-5409 is the protein SEQ ID NO: 2 and said at least one protein of the phage CNCM 1-5410 is the protein SEQ ID NO: 3. Even more particularly, said marker conjugated to the phage proteins is a gold nanoparticle.

[0061] In particular, the marking area comprises a marker conjugated to the CNCM 1-5408 phage coupled to an anti-S. aureus antibody, a marker conjugated to the phage CNCM 1-5409 coupled to an anti-S. aureus antibody, a phage-conjugated marker CNCM 1-5410 coupled to an anti-S. aureus antibody, a phage-conjugated marker CNCM 1-5491 coupled to an anti-S. aureus antibody and / or a marker conjugated to phage CNCM 1-5492 coupled to an anti-S. aureus antibody. In particular, it comprises a marker conjugated to a protein of phage CNCM 1-5408 coupled to an anti-S. aureus antibody, a marker conjugated to a protein of phage CNVM I-5409 coupled to an anti-S. aureus antibody, a marker conjugated to a protein of phage CNCM 1-5410 coupled to an anti-S. aureus antibody, a marker conjugated to a protein of phage CNCM 1-5491 coupled to an anti-S. aureus antibody and / or a marker conjugated to a protein of phage CNCM 1-5492 coupled to an anti-S. aureus antibody. In particular, the marking area comprises a marker conjugated to an anti-S. aureus antibody coupled to the CNCM 1-5408 phage, a marker conjugated to a anti-S. aureus antibody coupled to phage CNCM 1-5409, a marker conjugated to a anti-S. aureus antibody coupled to phage CNCM 1-5410, a marker conjugated to a anti-S. aureus antibody coupled to phage CNCM 1-5491 and / or a marker conjugated to an anti-S. aureus antibody coupled to the CNCM 1-5492 phage. In particular, in these examples of conjugation of the marker, said at least one protein of the CNCM 1-5408 phage is the protein SEQ ID NO: 1, said at least one protein of the CNCM 1-5409 phage is the protein SEQ ID NO: 2 and said at least one protein of the CNCM 1-5410 phage is the protein SEQ ID NO: 3. Even more particularly, said marker conjugated to the phage proteins is a gold nanoparticle.

[0062] In particular, the detection zone comprises a CNCM 1-5408 phage, a CNCM 1-5409 phage, a CNCM 1-5410 phage, a CNCM 1-5491 and / or CNCM 1-5492 phage. In particular, the detection zone comprises a CNCM 1-5408 phage, a CNCM 1-5409 phage and a CNCM 1-5410 phage.

[0063] In particular, the detection zone comprises at least one protein of phage CNCM 1-5408, at least one protein of phage CNCM 1-5409, at least one protein of phage CNCM 1-5410, at least one protein of phage CNCM 1-5491 and / or at least one protein of phage CNCM 1-5492. In particular, the detection zone comprises at least one protein of phage CNCM 1-5408, at least one protein of phage CNCM 1-5409 and at least one protein of phage CNCM 1-5410. In particular, said at least one protein of phage CNCM 1-5408 is the protein SEQ ID NO: 1, said at least one protein of phage CNCM 1-5409 is the protein SEQ ID NO: 2 and said at least one protein of phage CNCM 1-5410 is the protein SEQ ID NO: 3. Thus, more particularly, the detection zone comprises a protein of phage CNCM 1-5408 of SEQ ID NO: 1, a protein of phage CNCM 1-5409 of SEQ ID NO: 2 and / or a protein of phage CNCM 1-5410 of SEQ ID NO: 3.

[0064] In another embodiment, said lateral flow chromatography strip comprises in order at least: - a contact part comprising a contact area with the sample; - a marking part comprising a marking area which comprises a marker conjugated to at least one ligand specific to the bacterium of interest chosen from at least one bacteriophage specific to the bacterium of interest, at least one protein of at least one bacteriophage specific to the bacterium of interest, at least one bacteriophage specific to the bacterium of interest coupled to an antibody directed against the bacterium of interest, at least one protein of a bacteriophage specific to the bacterium of interest coupled to an antibody directed against the bacterium of interest, - a detection part comprising a detection zone for the bacteria of interest which comprises at least one ligand specific to the bacteria of interest, - an absorbent part.

[0065] In particular, said at least one ligand specific for the bacterium of interest included in the detection zone is at least one antibody directed against the bacterium of interest, at least one aptamer specific for the bacterium of interest, at least one bacteriophage specific for the bacterium of interest, at least one protein of at least one bacteriophage specific for the bacterium of interest, at least one bacteriophage specific for the bacterium of interest coupled to an antibody directed against the bacterium of interest, at least one protein of a bacteriophage specific for the bacterium of interest coupled to an antibody directed against the bacterium of interest.

[0066] In particular, said at least one protein of at least one bacteriophage specific to the bacterium of interest cited above as ligand on the detection zone or conjugated to a label on the labeling zone, is an RBP protein.

[0067] In a more particular embodiment, the present invention relates to a lateral flow chromatography strip for detecting S. aureus in a sample, comprising in order at least: - a contact part comprising a contact area with the sample; - a labeling portion comprising a labeling area which comprises a label conjugated to at least one ligand specific for S. aureus chosen from: at least one bacteriophage specific for S. aureus, at least one protein of at least one bacteriophage specific for S. aureus, at least one bacteriophage specific for S. aureus coupled to an antibody directed against S. aureus, at least one protein of a bacteriophage specific for S. aureus coupled to an antibody directed against S. aureus; - a detection part comprising an S. aureus detection zone which comprises at least one S. aureus-specific ligand; - an absorbent part.

[0068] In particular, the marking zone comprises a marker conjugated to at least one bacteriophage specific for S. aureus. In particular, it comprises a marker conjugated to phage CNCM 1-5408, a marker conjugated to phage CNCM 1-5409, a marker conjugated to phage CNCM 1-5410, a marker conjugated to phage CNCM 1-5491 and / or a marker conjugated to phage CNCM 1-5492. More particularly, it comprises a marker conjugated to the CNCM 1-5408 phage, a marker conjugated to the CNCM 1-5409 phage and a marker conjugated to the CNCM 1-5410 phage. Even more particularly, said marker conjugated to these phages is a gold nanoparticle.

[0069] In particular, the marking zone comprises a marker conjugated to at least one protein of at least one bacteriophage specific for S. aureus. In particular, said at least one protein is an RBP. In particular, the marking area comprises a marker conjugated to at least one protein of phage CNCM 1-5408, a marker conjugated to at least one protein of phage CNCM 1-5409, a marker conjugated to at least one protein of phage CNCM 1-5410, a marker conjugated to at least one protein of phage CNCM 1-5491 and / or a marker conjugated to at least one protein of phage CNCM 1-5492.More particularly, it comprises a marker conjugated to at least one protein of the phage CNCM 1-5408, a marker conjugated to at least one protein of the phage CNCM 1-5409 and a marker conjugated to at least one protein of the phage CNCM 1-5410. In particular, in these examples of conjugation of the marker, said at least one protein of the phage CNCM 1-5408 is the protein SEQ ID NO: 1, said at least one protein of the phage CNCM 1-5409 is the protein SEQ ID NO: 2 and said at least one protein of the phage CNCM 1-5410 is the protein SEQ ID NO: 3. Even more particularly, said marker conjugated to these phage proteins is a gold nanoparticle.

[0070] In particular, the detection zone comprises an anti-S. aureus antibody or an aptamer specific for S. aureus. In particular, the detection zone comprises at least one bacteriophage specific for the bacterium of interest, more particularly a bacteriophage CNCM 1-5408, a bacteriophage CNCM 1-5409, a bacteriophage CNCM 1-5410, a bacteriophage CNCM 1-5491 and / or a bacteriophage CNCM 1-5492. More particularly, it comprises a bacteriophage CNCM 1-5408, a bacteriophage CNCM 1-5409 and a bacteriophage CNCM 1-5410.

[0071] In particular, the detection zone comprises at least one protein of at least one bacteriophage specific for S. aureus, in particular an RBP. More particularly, it comprises at least one protein of the bacteriophage CNCM 1-5408, at least one protein of the bacteriophage CNCM 1-5409, at least one protein of the bacteriophage CNCM 1-5410, at least one protein of the bacteriophage CNCM 1-5491 and / or at least one protein of the bacteriophage CNCM 1-5492. Even more particularly, it comprises at least one protein of the bacteriophage CNCM 1-5408, at least one protein of the bacteriophage CNCM 1-5409 and at least one protein of the bacteriophage CNCM 1-5410. In particular, said at least one protein of phage CNCM 1-5408 is the protein SEQ ID NO: 1, said at least one protein of phage CNCM 1-5409 is the protein SEQ ID NO: 2 and said at least one protein of phage CNCM 1-5410 is the protein SEQ ID NO: 3. Thus, more particularly, the detection zone comprises a protein of phage CNCM 1-5408 of SEQ ID NO: 1, a protein of phage CNCM 1-5409 of SEQ ID NO: 2 and / or a protein of phage CNCM 1-5410 of SEQ ID NO: 3.

[0072] In particular, the detection zone comprises at least one bacteriophage specific for S. aureus coupled to an antibody directed against S. aureus and / or at least one protein of a bacteriophage specific for S. aureus coupled to an antibody directed against S. aureus, in particular said bacteriophage is chosen from bacteriophages CNCM I-5408, CNCM I-5409, CNCM I-5410, CNCM I-5491 and CNCM I-5492, and said protein is chosen from the proteins of these phages. In particular, said at least one protein of phage CNCM I-5408 is the protein SEQ ID NO: 1, said at least one protein of phage CNCM I-5409 is the protein SEQ ID NO: 2 and said at least one protein of phage CNCM I-5410 is the protein SEQ ID NO: 3.

[0073] In a particular embodiment, when the strip comprises at least four parts, one of the ends of the contact part is superimposed with one of the ends of the part downstream thereof to form a first superposition zone; one of the ends of the marking part is superimposed with one of the ends of the part upstream thereof to form a second superposition zone and the other end of the marking part is superimposed with one of the ends of the part downstream thereof to form a third superposition zone; one of the ends of the detection part is superimposed with one of the ends of the part upstream thereof to form a fourth superposition zone and the other end of the detection part is superimposed with one of the ends of the part downstream thereof to form a fifth superposition zone;and one of the ends of the absorbing portion is superimposed with one of the ends of the portion downstream thereof to form a sixth superposition zone. In particular, the first, second, third, fourth, fifth and sixth superposition zones are separated from each other. In particular, the contact zone is distinct from the first superposition zone. In particular, the marking zone is distinct from the second and third superposition zones. In particular, the detection zone is distinct from the fourth and fifth superposition zones. ;

[0074] In a particular embodiment, one of the ends of the marking part is superimposed on one of the ends of the contact part and the other end of the marking part is superimposed on one of the ends of the detection part; the other end of the detection part being superimposed with one of the ends of the absorbent part.

[0075] In a particular embodiment, one of the ends of the marking portion is superimposed on one of the ends of the contact portion to form a first superposition zone, and the other end of the marking portion is su perposed at one end of the detection portion to form a second superposition zone; the other end of the detection portion being superposed with one end of the absorbing portion to form a third superposition zone. In particular, the first, second and third superposition zones are separated from each other. In particular, the contact zone is distinct from the first superposition zone. In particular, the marking zone is distinct from the first and second superposition zones. In particular, the detection zone is distinct from the second and third superposition zones.

[0076] In a particular embodiment, the detection zone is a line transverse to the strip, thus forming a detection line or test line.

[0077] Optionally, the detection portion may further comprise a control zone as described previously.

[0078] In a particular embodiment of the strips according to the present invention, the bacterium of interest to be detected is S. aureus, and said at least one bacteriophage specific for a bacterium of interest is at least one bacteriophage specific for S. aureus chosen from bacteriophage CNCM 1-5408, bacteriophage CNCM 1-5409, bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5491 and / or bacteriophage CNCM 1-5492, and said at least one protein of at least one bacteriophage specific for a bacterium of interest is at least one protein of at least one bacteriophage specific for S.aureus selected from at least one protein of the bacteriophage CNCM 1-5408, in particular the protein SEQ ID NO: 1, at least one protein of the bacteriophage CNCM 1-5409, in particular the protein SEQ ID NO: 2, at least one protein of the bacteriophage CNCM 1-5410, in particular the protein SEQ ID NO: 3, at least one protein of the bacteriophage CNCM 1-5491, and / or at least one protein of the bacteriophage CNCM 1-5492.

[0079] A second aspect of the present invention relates to a method of detecting a bacterium of interest in a sample using the lateral flow chromatography strips described above.

[0080] In a particular embodiment, the method for detecting a bacterium of interest, in particular S. aureus, in a sample comprises: - a step of marking the bacteria or the bacteria of interest in the sample; - a step of bringing the sample into contact with the contact zone of said strip; - a step of detecting the marker on the detection zone - a step of analyzing the presence or absence of the bacteria of interest in the sample.

[0081] The marking step is carried out in the sample, i.e. prior to the bringing the sample into contact with the contact area of ​​the strip. This embodiment of the detection method is applicable whether or not the lateral flow chromatography strip used includes a labeling portion. Thus, this embodiment of the detection method applies to all the strips described in the present application. When the strip used in this detection method contains a labeling portion, double labeling of the bacteria of interest is then carried out, the marker used in the labeling step in the sample and the marker included in the labeling area of ​​the strip being able to be identical or different.

[0082] The labeling step is carried out with an unconjugated label or a conjugated label as defined above. The conjugated label may be conjugated to at least one specific ligand as defined above. Those skilled in the art know how to carry out this labeling step depending on the label chosen. In particular, when it is a conjugated label, an incubation of the sample with the conjugated label may be carried out.

[0083] A person skilled in the art knows how to adapt the detection step according to the marker used. In particular, when the marker is a gold nanoparticle, the detection is done in the visible range. In particular, when the marker used is a fluorescent marker, a fluorescence reader is used. In particular, when the marker used is an enzyme, the substrate of the reaction that it catalyzes is added.More specifically, when it comes to horseradish peroxidase that catalyzes the conversion of chromogenic substrates into colored compounds, or produces light from chemiluminescent substrates, the added substrate is for example 2,2'-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS), 1,2-diaminobenzene (OPD), 3,3'-Diaminobenzidine (DAB), 3-Amino-9-ethylcarbazole (AEC) or 3,3',5,5'-tetramethylbenzidine (TMB) for color reactions; homovanillic acid and tyramine for fluorescence spectroscopy; luminol for light production.

[0084] The analysis of the presence of the bacteria of interest in the analyzed sample is done when the marker is detected on the detection zone. In particular, when the marker is a gold nanoparticle, a colored signal visible to the naked eye appears. In particular, when the marker used is a fluorescent marker (conjugated or not), a fluorescent signal appears on the detection zone. When the marker used is an enzyme such as horseradish peroxidase, a substrate such as those listed above is added and a colored signal visible to the naked eye, a fluorescent signal or a luminescent signal is observed depending on the substrate.

[0085] The analysis of the absence of the bacteria of interest in the sample is done when the marker is not detected on the detection zone.

[0086] When the lateral flow chromatography strip used for the detection method comprises a labeling portion, the step of labeling the bacteria or the bacterium of interest in the sample is optional. Thus, when the lateral flow chromatography strip used for the detection method comprises a labeling portion, the method for detecting a bacterium of interest, in particular S. aureus, in a sample may comprise: - a step of bringing the sample into contact with the contact zone of said strip; - a step of detecting the marker on the detection zone; - a step of analyzing the presence or absence of the bacteria of interest in the sample. In another particular embodiment, the method for detecting a bacteria of interest, in particular S. aureus, in a sample comprises: - a step of labeling the bacterium of interest in the sample with a marker conjugated to at least one ligand specific to the bacterium of interest chosen from: at least one bacteriophage specific to the bacterium of interest, at least one protein of at least one bacteriophage specific to the bacterium of interest, at least one bacteriophage specific to the bacterium of interest coupled to an antibody directed against the bacterium of interest and / or at least one protein of a bacteriophage specific to the bacterium of interest coupled to an antibody directed against the bacterium of interest; - a step of bringing the sample into contact with the contact zone of a strip comprising at least a contact portion comprising a sample contact area; a detection part comprising a detection zone of the bacteria of interest which comprises at least one antibody directed against the bacteria of interest and / or at least one aptamer specific to the bacteria of interest, in particular said bacteria of interest is S. aureus, an absorbent part; - a step of detecting the marker on the detection zone; - a step of analyzing the presence or absence of the bacteria in the sample.

[0087] In other words, in this particular embodiment, said detection zone of the strip comprises at least one ligand specific to the bacteria of interest other than a phage specific to the bacteria of interest or a protein of a phage specific to the bacteria of interest.

[0088] In a particular embodiment, said at least one protein of at least one bacteriophage specific to the bacterium of interest used in the labeling step, coupled or not to an antibody, is an RBP protein.

[0089] In a particular embodiment, the bacterium of interest is S. aureus and said specific ligands conjugated to the marker, used in the marking step, are read as specific ligands of S. aureus.

[0090] Thus, the labeling step may comprise a label conjugated to at least one bacteriophage specific for S. aureus. In particular, it is a label conjugated to phage CNCM 1-5408, a label conjugated to phage CNCM 1-5409, a label conjugated to phage CNCM 1-5410, a label conjugated to phage CNCM 1-5491 and / or a label conjugated to phage CNCM 1-5492. More particularly, it is a label conjugated to phage CNCM 1-5408, a label conjugated to phage CNCM 1-5409 and a label conjugated to phage CNCM 1-5410. Even more particularly, said phage-conjugated label is a gold nanoparticle.

[0091] The labeling step in the sample may also comprise a label conjugated to at least one protein of at least one bacteriophage specific for S. aureus. In particular, said at least one protein is an RBP. In particular, it is a label conjugated to at least one protein of the phage CNCM 1-5408, a label conjugated to at least one protein of the phage CNCM 1-5409, a label conjugated to at least one protein of the phage CNCM 1-5410, a label conjugated to at least one protein of the phage CNCM 1-5491 and / or a label conjugated to at least one protein of the phage CNCM 1-5492. More particularly, it is a marker conjugated to at least one protein of the phage CNCM 1-5408, a marker conjugated to at least one protein of the phage CNCM 1-5409 and a marker conjugated to at least one protein of the phage CNCM 1-5410.In particular, said at least one protein of the CNCM I-5408 phage is the protein SEQ ID NO: 1, said at least one protein of the CNCM I-5409 phage is the protein SEQ ID NO: 2 and said at least one protein of the CNCM I-5410 phage is the protein SEQ ID NO: 3. Even more particularly, said marker conjugated to these phage proteins is a gold nanoparticle.

[0092] In particular, the labeling step in the sample may comprise a CNCM 1-5408 phage-conjugated marker coupled to an anti-S. aureus antibody, a CNCM 1-5409 phage-conjugated marker coupled to an anti-S. aureus antibody, a CNCM 1-5410 phage-conjugated marker coupled to an anti-S. aureus antibody, a CNCM 1-5491 phage-conjugated marker coupled to an anti-S. aureus antibody and / or a CNCM 1-5492 phage-conjugated marker coupled to an anti-S. aureus antibody. In particular, it may comprise a marker conjugated to a protein of the phage CNCM 1-5408 coupled to an anti-S. aureus antibody, a marker conjugated to a protein of the phage CNCM 1-5409 coupled to an anti-S. aureus antibody, a marker conjugated to a protein of the phage CNCM 1-5410 coupled to an anti-S. aureus antibody, a marker conjugated to a protein of the phage CNCM 1-5491 coupled to an anti-S. aureus antibody and / or a marker conjugated to a protein of the phage CNCM 1-5492 coupled to an anti-S.aureus. In particular, it may comprise a marker conjugated to an anti-S. aureus antibody coupled to the CNCM 1-5408 phage, a marker. conjugated to an anti-S. aureus antibody coupled to phage CNCM 1-5409, a marker conjugated to an anti-S. aureus antibody coupled to phage CNCM 1-5410, a marker conjugated to an anti-S. aureus antibody coupled to phage CNCM 1-5491 and / or a marker conjugated to an anti-S. aureus antibody coupled to phage CNCM 1-5492. In particular, in these examples of marker conjugation, said at least one protein of phage CNCM 1-5408 is the protein SEQ ID NO: 1, said at least one protein of phage CNCM 1-5409 is the protein SEQ ID NO: 2 and said at least one protein of phage CNCM 1-5410 is the protein SEQ ID NO: 3. Even more particularly, the said marker conjugated to phage proteins is a gold nanoparticle.

[0093] Optionally, the methods for detecting a bacterium of interest described in the present application, first comprise a step of mixing a surfactant with the sample. For the purposes of the present invention, a surfactant is an amphiphilic molecule making it possible to lower the surface tension of an aqueous solution. In particular, the surfactant is added to the sample at a rate of 0.5% to 12% (w / v). For example, the surfactant is Tween 20.

[0094] A third aspect of the present invention relates to a kit for detecting a bacterium of interest in a sample using the lateral flow chromatography strips described above.

[0095] In a particular embodiment, the kit for detecting a bacterium of interest, in particular S. aureus, in a sample comprises: - a strip as described in this application; - a container intended to receive the sample; - a container containing a marker.

[0096] The label may be an unconjugated label or a conjugated label as defined above. The conjugated label may be conjugated to at least one specific ligand as defined above. In a particular embodiment, the label may be included in the container intended to receive the sample.

[0097] This embodiment of the kit may comprise a lateral flow chromatography strip with or without a labeling portion. Thus, this embodiment of the detection kit applies to all the strips described in the present application.

[0098] When the lateral flow chromatography strip comprises a labeling portion, the container of the kit optionally comprises a label. Thus, when the lateral flow chromatography strip comprises a labeling portion, the kit for detecting a bacterium of interest, in particular S. aureus, in a sample comprises: - said strip; - a container intended to receive the sample.

[0099] In another particular embodiment, the kit for detecting a bacterium of interest, particularly S. aureus, in a sample includes: - a strip comprising at least: a contact portion comprising a sample contact area; a detection part comprising a detection zone of the bacteria of interest which comprises at least one antibody directed against the bacteria of interest and / or at least one aptamer specific to the bacteria of interest, in particular said bacteria of interest is S. aureus, an absorbent part; - a container intended to receive the sample - a container comprising a marker conjugated to a ligand specific to the bacterium of interest chosen from: at least one bacteriophage specific to the bacterium of interest, at least one protein of at least one bacteriophage specific to the bacterium of interest, at least one bacteriophage specific to the bacterium of interest coupled to an antibody directed against the bacterium of interest, at least one protein of a bacteriophage specific to the bacterium of interest coupled to an antibody directed against the bacterium of interest.

[0100] In other words, in this particular embodiment, said detection zone of the strip comprises at least one ligand specific to the bacterium of interest other than a phage specific to the bacterium of interest or a protein of a phage specific to the bacterium of interest.

[0101] In a particular embodiment, said at least one protein of at least one bacteriophage specific to the bacterium of interest conjugated to the marker, coupled or not to an antibody, is an RBP protein.

[0102] In a particular embodiment, the marker conjugated to a ligand specific to the bacterium of interest may be included in the container intended to receive the sample.

[0103] In a particular embodiment, it is a kit for detecting the bacterium of interest S. aureus and said specific ligands conjugated to the marker are read as ligands specific to S. aureus.

[0104] In a particular embodiment, the bacterium of interest is S. aureus and these specific ligands used in the labeling step, in conjugation with a label, read as ligands specific to S. aureus.

[0105] In particular, this embodiment of the kit is intended to detect S. aureus in a sample. Thus, the container may comprise a marker conjugated to at least one bacteriophage specific for S. aureus. In particular, it is a marker conjugated to phage CNCM 1-5408, a marker conjugated to phage CNCM 1-5409, a marker conjugated to phage CNCM 1-5410, a marker conjugated to phage CNCM 1-5491 and / or a marker conjugated to phage CNCM 1-5492. More particularly, it is a marker conjugated to phage CNCM 1-5408, a marker conjugated to phage CNCM 1-5409 and a marker conjugated to the CNCM phage 1-5410. Even more particularly, said marker conjugated to these phages is a gold nanoparticle.

[0106] The container may also comprise a marker conjugated to at least one protein of at least one bacteriophage specific for S. aureus. In particular, said at least one protein is an RBP. In particular, it is a marker conjugated to at least one protein of the phage CNCM 1-5408, a marker conjugated to at least one protein of the phage CNCM 1-5409, a marker conjugated to at least one protein of the phage CNCM 1-5410, a marker conjugated to at least one protein of the phage CNCM 1-5491 and / or a marker conjugated to at least one protein of the phage CNCM 1-5492. More particularly, it is a marker conjugated to at least one protein of the phage CNCM 1-5408, a marker conjugated to at least one protein of the phage CNCM 1-5409 and a marker conjugated to at least one protein of the phage CNCM 1-5410.In particular, said at least one protein of phage CNCM 1-5408 is protein SEQ ID NO: 1, said at least one protein of phage CNCM 1-5409 is protein SEQ ID NO: 2 and said at least one protein of phage CNCM 1-5410 is protein SEQ ID NO: 3. Even more particularly, said marker conjugated to these phage proteins is a gold nanoparticle.

[0107] In particular, the container may comprise a marker conjugated to phage CNCM I-5408 coupled to an anti-S. aureus antibody, a marker conjugated to phage CNCM I-5409 coupled to an anti-S. aureus antibody, a marker conjugated to phage CNCM I-5410 coupled to an anti-S. aureus antibody, a marker conjugated to phage CNCM I-5491 coupled to an anti-S. aureus antibody and / or a marker conjugated to phage CNCM I-5492 coupled to an anti-S. aureus antibody. In particular, it may comprise a marker conjugated to a protein of the phage CNCM 1-5408 coupled to an anti-S. aureus antibody, a marker conjugated to a protein of the phage CNCM 1-5409 coupled to an anti-S. aureus antibody, a marker conjugated to a protein of the phage CNCM 1-5410 coupled to an anti-S. aureus antibody, a marker conjugated to a protein of the phage CNCM 1-5491 coupled to an anti-S. aureus antibody and / or a marker conjugated to a protein of the phage CNCM 1-5492 coupled to an anti-S. aureus antibody.In particular, it may comprise a marker conjugated to an anti-S. aureus antibody coupled to phage CNCM 1-5408, a marker conjugated to an anti-S. aureus antibody coupled to phage CNCM 1-5409, a marker conjugated to an anti-S. aureus antibody coupled to phage CNCM 1-5410, a marker conjugated to an anti-S. aureus antibody coupled to phage CNCM 1-5491 and / or a marker conjugated to an anti-S. aureus antibody coupled to phage CNCM 1-5492. In particular, in these examples of conjugation of the marker, said at least one protein of the phage CNCM I-5408 is the protein SEQ ID NO: 1, said at least one protein of the phage CNCM I-5409 is the protein SEQ ID NO: 2 and said at least one protein of the phage CNCM I- . 5410 is the protein SEQ ID NO: 3. Even more particularly, said marker conjugated to phage proteins is a gold nanoparticle.

[0108] For the kits described in the present application, the person skilled in the art knows how to select a container with adequate proportions to receive the sample and / or to include the necessary volume of marker. In particular, if the container is intended to contain the strip in order to implement the detection method, the person skilled in the art knows how to choose a container with adequate proportions to contain the strip, the sample and optionally the marker, and he knows how to adapt the sample volume and the marker volume (if necessary), so that only the sample or the sample and marker mixture is in contact with the contact area of ​​the strip when implementing the detection method. For example, the container will include a graduation indicating the maximum volume of sample to be added.

[0109] Optionally, the kits described in the present application comprise a container comprising a surfactant. In particular, it comprises a volume of surfactant representing from 0.5 to 12% (w / v) of the volume of sample with which the surfactant will be mixed. In a particular embodiment, the surfactant may be included in the container intended to receive the sample, or in a container intended to receive the sample and comprising a marker.

[0110] According to a fourth aspect, the present invention relates to the use of at least one bacteriophage specific for a bacterium of interest and / or at least one protein of at least one bacteriophage specific for a bacterium of interest for detecting said bacterium of interest in a sample, characterized in that said at least one bacteriophage specific for the bacterium of interest and / or said at least one protein of at least one bacteriophage specific for the bacterium of interest are used in a lateral flow chromatography device. In particular, a lateral flow chromatography device is a lateral flow chromatography strip. More particularly, it is a strip as described in the present application.

[0111] In a particular mode of use, the bacterium of interest is Staphylococcus aureus. Thus, said at least one bacteriophage is specific for S. aureus. In a more particular mode, said at least one bacteriophage specific for S. aureus is bacteriophage CNCM 1-5408, bacteriophage CNCM 1-5409, bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5491 and / or bacteriophage CNCM 1-5492.

[0112] In particular, it may involve the use of two bacteriophages specific to S. aureus chosen from this list, such as for example bacteriophage CNCM I-5408 and bacteriophage CNCM 1-5409, bacteriophage CNCM 1-5409 and bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5408 and bacteriophage CNCM I-5410, bacteriophage CNCM 1-5408 and bacteriophage CNCM 1-5491, bacteriophage CNCM 1-5409 and bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5409 and bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5409 and bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5409 and bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5409 and bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5409 and bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5410 ... riophage CNCM 1-5409 and bacteriophage CNCM 1-5491, bacteriophage CNCM I-5410 and bacteriophage CNCM 1-5491, bacteriophage CNCM 1-5408 and bacteriophage CNCM 1-5492, bacteriophage CNCM 1-5409 and bacteriophage CNCM I-5492, bacteriophage CNCM 1-5410 and bacteriophage CNCM 1-5492 or bacteriophage CNCM 1-5491 and bacteriophage CNCM 1-5492. In particular, it may involve the use of three bacteriophages specific to S.aureus selected from this list, such as for example the bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409 and CNCM 1-5410, the bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5491 and CNCM 1-5492, the bacteriophages deposited under numbers CNCM 1-5409, CNCM 1-5491 and CNCM 1-5492, the bacteriophages deposited under numbers CNCM 1-5410, CNCM 1-5491 and CNCM 1-5492, the bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409 and CNCM 1-5491, the bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5410 and CNCM 1-5491, the bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409 and CNCM 1-5492, the bacteriophages deposited under numbers CNCM 1-5408, CNCM I-5410 and CNCM 1-5492, the bacteriophages deposited under numbers CNCM 1-5409, CNCM 1-5410 and CNCM 1-5491, the bacteriophages deposited under numbers CNCM 1-5409, CNCM 1-5410 and CNCM 1-5492. In particular, it may involve the use of four bacteriophages specific to S.aureus such as bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409, CNCM 1-5410 and CNCM 1-5491, bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409, CNCM I-5410 and CNCM 1-5492, bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5409, CNCM 1-5491 and CNCM 1-5492, bacteriophages deposited under numbers CNCM 1-5408, CNCM 1-5410, CNCM 1-5491 and CNCM 1-5492, bacteriophages deposited under numbers CNCM 1-5410, CNCM 1-5409, CNCM 1-5491 and CNCM 1-5492. In particular, it may involve the use of five bacteriophages specific to S. aureus such as the bacteriophages deposited under numbers CNCM I-5408, CNCM 1-5409, CNCM 1-5410, CNCM 1-5491 and CNCM 1-5492.

[0113] In the case of the use of at least one protein of at least one bacteriophage specific for a bacterium of interest, said at least one bacteriophage specific for a bacterium of interest is as defined above. Thus, in a particular mode of use, said at least one protein of at least one bacteriophage specific for a bacterium of interest is at least one protein of at least one bacteriophage specific for S. aureus. In particular, it is a binding protein (RBP). More particularly, said at least one protein of at least one bacteriophage specific for S. aureus is at least one protein of the bacteriophage CNCM 1-5408, at least one protein of the phage CNCM 1-5409, at least one protein of the bacteriophage CNCM 1-5410, at least one protein of the phage CNCM 1-5491 and / or at least one protein of the bacteriophage CNCM 1-5492. In particular, it concerns the use of at least one protein of the bacteriophage CNCM 1-5408 and at least one protein of the bacteriophage CNCM 1-5409, at least one protein of the bacteriophage CNCM 1-5409 and at least one protein of the bacteriophage CNCM 1-5410, at least one protein of the bacteriophage CNCM 1-5408 and at least one protein of the bacteriophage CNCM 1-5410, at least one protein of the bacteriophage CNCM 1-5408 and at least one protein of the bacteriophage CNCM 1-5491, at least one protein of the bacteriophage CNCM I-5409 and at least one protein of the bacteriophage CNCM 1-5491, at least one protein of the bacteriophage CNCM 1-5410 and of at least one protein of bacteriophage CNCM 1-5491, of at least one protein of bacteriophage CNCM 1-5408 and of at least one protein of bacteriophage CNCM 1-5492, of at least one protein of bacteriophage CNCM 1-5409 and of at least one protein of bacteriophage CNCM 1-5492,of at least one protein of the bacteriophage CNCM 1-5410 and at least one protein of the bacteriophage CNCM 1-5492, of at least one protein of the bacteriophage CNCM I-5491 and of at least one protein of the bacteriophage CNCM 1-5492. In particular, it may be the use of at least one protein of the bacteriophage CNCM 1-5408, of at least one protein of the bacteriophage CNCM 1-5409 and of at least one protein of the bacteriophage CNCM 1-5410; of at least one protein of the bacteriophage CNCM 1-5408, of at least one protein of the bacteriophage CNCM 1-5491 and of at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of the bacteriophage CNCM 1-5409, of at least one protein of the bacteriophage CNCM 1-5491 and of at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of the bacteriophage CNCM 1-5410, of at least one protein of the bacteriophage CNCM 1-5491 and of at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of the bacteriophage CNCM 1-5408,of at least one protein of the bacteriophage CNCM 1-5409 and at least one protein of the bacteriophage CNCM 1-5491; of at least one protein of the bacteriophage CNCM 1-5408, of at least one protein of the bacteriophage CNCM 1-5410 and of at least one protein of the bacteriophage CNCM 1-5491; of at least one protein of the bacteriophage CNCM 1-5408, of at least one protein of the bacteriophage CNCM 1-5409 and of at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of the bacteriophage CNCM 1-5408, of at least one protein of the bacteriophage CNCM 1-5410 and of at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of the bacteriophage CNCM 1-5409, of at least one protein of the bacteriophage CNCM 1-5410 and of at least one protein of the bacteriophage CNCM 1-5491; of at least one protein of the bacteriophage CNCM 1-5409, of at least one protein of the bacteriophage CNCM 1-5410 and of at least one protein of the bacteriophage CNCM 1-5492. In particular, it concerns the use of at least one protein of the bacteriophage CNCM 1-5408,of at least one protein of the bacteriophage CNCM 1-5409, of at least one protein of the bacteriophage CNCM 1-5410 and of at least, a protein of the bacteriophage CNCM 1-5491; at least one protein of the bacteriophage CNCM 1-5408, at least one protein of the bacteriophage CNCM 1-5409, at least one protein of the bacteriophage CNCM 1-5410 and at least one protein of the bacteriophage CNCM 1-5492; at least one protein of the bacteriophage CNCM I-5408, at least one protein of the bacteriophage CNCM 1-5409, at least one protein of the bacteriophage CNCM 1-5491 and at least one protein of the bacteriophage CNCM 1-5492; of at least one protein of bacteriophage CNCM 1-5408, of at least one protein of bacteriophage CNCM 1-5410, of at least one protein of bacteriophage CNCM 1-5491 and of at least one protein of bacteriophage CNCM 1-5492; of at least one protein of bacteriophage CNCM 1-5410, of at least one protein of bacteriophage CNCM 1-5409, of at least one protein of bacteriophage CNCM I-5491 and of at least one protein of bacteriophage CNCM 1-5492.In particular, it concerns the use of at least one protein of bacteriophage CNCM 1-5408, at least one protein of bacteriophage CNCM 1-5409, at least one protein of bacteriophage CNCM 1-5410, at least one protein of bacteriophage CNCM 1-5491 and at least one protein of bacteriophage CNCM 1-5492.

[0114] In a particular mode of use, said at least one protein of at least one bacteriophage specific to a bacterium of interest or said at least one protein of at least one bacteriophage specific to S. aureus is a receptor binding protein (RBP). In a more particular mode of use, this involves the use of at least one RBP protein of bacteriophage CNCM 1-5408, at least one RBP of bacteriophage CNCM 1-5409, at least one RBP of bacteriophage CNCM 1-5410, at least one RBP of bacteriophage CNCM 1-5491, and / or at least one RBP of bacteriophage CNCM 1-5492.

[0115] Even more particularly, said at least one RBP protein of the bacteriophage CNCM 1-5408 is the protein SEQ ID NO: 1; said at least one RBP protein of the bacteriophage CNCM 1-5409 is the protein SEQ ID NO: 2; said at least one RBP protein of the bacteriophage CNCM 1-5410 is the protein SEQ ID NO: 3. Brief description of the drawings Fig.l

[0116] [Fig.l] Structure of a phage; Fig. 2

[0117] [Fig.2] Schematic of the magnetic bead method for assessing specificity of interaction between phage proteins and bacteria: 1. Addition of bacteria into a tube containing magnetic beads coated with phage proteins; 2. Binding of bacteria to proteins fixed on the magnetic beads (if specific recognition); 3. Precipitation of the magnetic beads using a magnetic support; 4. Removal of the supernatant (bacteria not specifically bound to the beads); 5. Resuspension of the magnetic beads in a buffer solution; 6. Spreading of the beads on a Petri dish with culture medium. Fig. 3

[0118] [Fig.3] Verification of the expression of an RBP protein (SEQ ID NO: 1) of the CNCM phage 1-5408, of an RBP protein (SEQ ID NO: 2) of the CNCM phage 1-5409 and of an RBP protein (SEQ ID NO: 3) of the CNCM phage 1-5410 on agarose gel; Fig. 4

[0119] [Fig.4] Test of the specificity of an RBP protein (SEQ ID NO: 1) of the CNCM I-5408 phage against S. aureus, S. epidermidis, S. algnetis; Fig. 5

[0120] [Fig.5] Affinity test of an RBP protein (SEQ ID NO: 1) of phage CNCM 1-5408, an RBP protein (SEQ ID NO: 2) of phage CNCM 1-5409 and an RBP protein (SEQ ID NO: 3) of phage CNCM 1-5410 against a strain of S. aureus (SA 81); Fig. 6

[0121] [Fig.6] LFA strip 1 comprising a contact portion 2 which comprises a contact area 3, a detection portion 4 which comprises a detection area 5, and an absorbent portion 6; Fig. 7

[0122] [Fig.7] LFA strip 1 comprising a contact portion 2 which comprises a contact area 3, a detection portion 4 which comprises a detection area 5 and a control area 9, and an absorbent portion 6; Fig. 8

[0123] [Fig.8] LFA strip 1 comprising a contact portion 2 which comprises a contact area 3, a marking portion 7 which comprises a marking area 8, a detection portion 4 which comprises a detection area 5, and an absorbent portion 6; Fig. 9

[0124] [Fig.9] LFA strip 1 comprising a contact portion 2 which comprises a contact area 3, a marking portion 7 which comprises a marking area 8, a detection portion 4 which comprises a detection area 5 and a control area 9, and an absorbent portion 6; Fig. 10

[0125] [Fig. 10] LFA strip 1 comprising a contact part 2 which comprises a contact area 3, a marking part 7 which comprises a marking area 8, a detection part 4 which comprises a detection area 5 and a control area 9, and an absorbent part 6, immersed in a sample to be analyzed; Fig. 11

[0126] [Fig. 11] Detection of S. aureus with different strips comprising a labeling part where anti-S. aureus antibodies labeled with AuNPs are deposited and a detection part where a phage 2 (CNCM 1-5408, noted P2), a phage 3 (CNCM 1-5409, noted P3), a phage 7 (CNCM 1-5410, noted P7), a protein of sequence SEQ ID NO: 1 (RB P of phage 2 noted Pr-P2), a protein of sequence SEQ ID NO: 2 (RBP of phage 3, noted Pr-P3) or a protein of sequence SEQ ID NO: 3 (RBP of phage 7, noted Pr-P7) is immobilized. Part A = controls, absence of bacteria in the tested sample; Part B = sample (PBS) artificially contaminated with S. aureus strain 79 (107 CFU / ml). Fig. 12

[0127] [Fig. 12] Diagram of an embodiment of the detection of a bacterium, in particular S. aureus, in a sample with a strip 1 comprising a contact part 2 comprising a contact area 3, a marking part 7 comprising a marking area 8 where an anti-S. aureus antibody conjugated to a gold nanoparticle is deposited, a detection part 4 comprising a detection area 5 where a phage or a phage protein specific to the bacterium is immobilized, and an absorbent part 6; Fig. 13

[0128] [Fig. 13] Diagram of an embodiment of the detection of a bacterium, in particular S. aureus, in a sample, to which an anti-S. aureus antibody conjugated to a gold nanoparticle is directly added, with a strip 1 comprising a contact part 2 comprising a contact area 3, a detection part 4 comprising a detection area 5 where a phage or a phage protein specific to the bacterium is immobilized, and an absorbent part 6; Fig. 14

[0129] [Fig. 14] Diagram of an embodiment of the detection of a bacterium, in particular S. aureus, in a sample, to which are directly added an anti-S. aureus antibody conjugated to a gold nanoparticle and a phage or a phage protein specific to the bacterium as well as Ca2+ to achieve the coupling between the two, with a strip 1 comprising a contact part 2 comprising a contact area 3, a detection part 4 comprising a detection area 5 where a phage or a phage protein specific to the bacterium is immobilized, and an absorbent part 6. Examples

[0130] Example 1: Activity of bacteriophages

[0131] 1.1. Determination of the activity of a bacteriophage on a bacterial strain

[0132] To identify whether a bacteriophage is specific to a bacterium, the spot method is used. On a Petri dish where a culture of bacteria in the exponential phase is spread, at least one spot comprising the bacteriophage is placed. After 18 hours of incubation at a temperature suitable for the bacterium, if a lysis zone is observed around the spot, this means that the bacteriophage is active for this bacterium, in other words that the bacteriophage is specific to this bacterium.

[0133] 1.2.Bacteriophages used

[0134] Three phages were tested in the present application: - the bacteriophage strain deposited at the CNCM under number CNCM 1-5408 (hereinafter referred to as phage 2); - the bacteriophage strain deposited at the CNCM under number CNCM 1-5409 (hereinafter referred to as phage 3); and - the bacteriophage strain deposited at the CNCM under number CNCM 1-5410 (hereinafter referred to as phage 7).

[0135] 1.3. Determination of the activity spectrum of isolated phages

[0136] The activity of these phages was tested on different bacterial strains from the Vetophage bacteria collection. These bacterial strains were isolated from samples collected from dairy farms in France. A total of 19 strains of S. aureus were used for the activity tests, as well as 5 strains of other staphylococcal species, namely S. haemolyticus, S. saprolyticus; S. chromogenes, S. agnetis, S. epidermidis and two strains of non-staphylococcal species, Streptococcus uberis and Escherichia coli.

[0137] These bacterial strains were grown on BHI agar and incubated at 37°C. The bacterial pellets were resuspended in phosphate-buffered saline (PBS) and adjusted to the required bacterial concentration.

[0138] Results

[0139] The activity of the phages, i.e. their ability to infect a bacterial strain, was tested by the spot method previously described on 19 strains of S. aureus, 5 strains of other Staphylococcus species (S. saprophyticus, S. chromogenes, S. haemolyticus, S. agnetis, S. epidermidis), and one strain of non-Staphylococcus bacteria (Streptococcus uberis). The ability to infect a bacterial strain means that the bacteriophage is capable of recognizing said bacterial strain and attaching itself to it with the aim of infecting it in order to destroy it.

[0140] Table 1 represents the spectrum of activity of phages against different strains of S. aureus. A phage is considered active (noted "x"), when a lysis range is obtained by the spot method. On the other hand, when no lysis is observed, the absence of activity is noted " / ".

[0141] [Tables 1] Bacteria Strains Phage 2 Phage 3 and Phage 7 Mix phages (2 / 3'7) 1 S. aureus 79 * XXX 2 S. aureus 81 XXXX 3 S. aureus C24.bx X 4 S.aureus F1.a XX X. b Saureus L5.a XX Xus. Q14.b XX 8 S.aureus U 5a .a X, XXX 9 S.aureus F2.ax X 10 S.aureus Ll.a XX 11 S aureus G6.b X 12 S aureus a X ililiilLJ X 13 S aureus 3 'f. X 14 S aureus R8c2 X ■SX? 15 S aureus 1Da2 X. ; ï 16 S aureus Z12c2b « « XX 17 S.awws 5S.d XX X. 18 Saurais 9L.a XXXX 19 Saurais Moqueuse XX Streptococcus uberts S.saprQpfryticus_sifbsp. 2Eb E2V-B J .............i.

[0142] These results show that: - The bacteriophage deposited at the CNCM under CNCM number 1-5408 (phage 2) infects 84% ​​of the strains; - The bacteriophage deposited at the CNCM under CNCM number 1-5409 (phage 3) infects 63% of the strains; - The bacteriophage deposited at the CNCM under number CNCM 1-5410 (phage 7) infects 68%; - The cocktail of three phages (2, 3 and 7) infects 100% of strains.

[0143] On the other hand, no activity of the phages alone or in mixture was observed against bacterial strains of a species other than S. aureus or bacterial strains of non-Staphylococcus species. This demonstrates the specificity of the phages for S. aureus.

[0144] Example 2: Selection of bacteriophage proteins

[0145] 2.1. Choice of bacteriophage proteins

[0146] The adsorption of bacteriophages into the host bacterium is carried out thanks to the specific recognition on the bacterial surface of phage binding proteins (Receptor Binding Protein or RBP), located at the base ("baseplate") of the phage tail ([Fig.l]).

[0147] In order to determine the binding specificity of phage proteins to S. aureus, the following proteins were selected and synthesized: - an RBP of phage 2 (SEQ ID NO: 1), - an RBP of phage 3 (SEQ ID NO: 2), - an RBP of phage 7 (SEQ ID NO: 3).

[0148] For this, phages 2, 3 and 7 were sequenced. The search for RBPs was performed from the complete annotations of the genomes of phages 2, 3 and 7 targeting the sequences of the “flat base” region. The alignment of the “flat base” sequences of each phage was carried out using the BlastX technique of the ORFs (open reading frame) of the phages.

[0149] The RBPs proteins were found at the level of the tail gene cluster around 55000 bp to 84000 bp and more precisely at the level of the “flat base” part.

[0150] The RBPs proteins SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, of phages 2, 3 and 7 were then produced in the BL21 bacterium by the cloning technique. For this, the genes corresponding to the phage proteins were cloned into a bacterial expression vector allowing the synthesis of the proteins in fusion with the enzyme Glutathione-S-Transferase (GST) by the host bacterium BL21.

[0151] 2.2. Evaluation of the binding specificity of phage proteins to 5. aureus

[0152] After purification, the proteins were separately conjugated with magnetic beads so that the surface of these beads was covered by one of the RBP proteins.

[0153] To evaluate the binding specificity of each of these proteins to the bacterial species S. aureus, the magnetic beads conjugated to the proteins to be tested were separately added to a mixture of bacteria comprising different species of Staphylococci (Staphylococcus aureus, Staphylococcus epidermidis and Staphylococcus algnetis).

[0154] If there is a specific interaction (an affinity) between the tested protein and one or more bacterial species in the mixture, the protein will capture the bacteria ([Fig.2]).

[0155] The beads are then separated from the liquid phase using a magnetic support, and washed several times with a buffer solution to eliminate non-specific interactions.

[0156] The beads are then recovered and spread in a Petri dish on a specific agar (Baird Parker). After 24 to 48 hours of incubation, the bacterial species fixed by the proteins are visually identified according to the morphology and color of the colonies developing on the agar. The number of bacteria retained is also determined by counting the colonies on the agar. The affinity or interaction of the protein tested with the target bacteria (S. aureus) is evaluated by the number of bacteria retained. The higher the number of target bacteria on the agar, the greater the affinity of the protein for the target bacteria.

[0157] 2.3. Results

[0158] The expression of the RBP proteins SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively, of phages 2, 3 and 7 in BL21 bacteria was verified on gel ( [Fig. 3]). The respective sizes of these RBPs of phages 2, 3 and 7 are 78.1 kDa, 100.8 kDa and 79.5 kDa.

[0159] The binding specificity of these proteins to the bacterial species S. aureus was then studied. The results showed that the RBP protein of phage 2 (SEQ ID NO: 2) has an affinity for the bacterium Staphylococcus aureus and only for this species of Staphylococcus ([Fig. 4]). In addition, the results in [Fig. 5] show that the RBP proteins SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively of phages 2, 3 and 7 have an affinity for the species S. aureus.

[0160] Example 3: LFA device with phages or phage proteins

[0161] 3.1. LFA device with phages or phage proteins

[0162] The inventors have developed a lateral flow chromatography strip 1 (LFA) for detecting the presence of a bacterium of interest in a sample, in particular the presence of S. aureus, using a phage or a protein of a phage specific to said bacterium of interest.

[0163] A first embodiment is a LFA strip 1 for detecting S. aureus in a sample, which comprises four parts: - a contact part 2 (sample pad) comprising a contact zone 3; - a marking part 7 (conjugal pad) comprising a marking area 8; - a detection part 4 (test pad) comprising a detection zone 5; - an absorbent part 6 (absorption pad); such that one of the ends of the marking part 7 is superimposed on one of the ends of the contact part 2, the other end of the marking part 7 is superimposed with one of the ends of the detection part 4, and the other end of the detection part 4 is superimposed with one of the ends of the absorbent part 6, to form respectively a first, a second and a third superposition zone, said superposition zones position being separated from each other.

[0164] The contact part 2 (sample pad) comprises a contact zone 3 intended to be brought into contact with the sample, and which is distinct from the first superposition zone. When the contact zone 3 is brought into contact with the sample, a migration flow of the sample by capillarity, from the contact part 2 to the absorbent part 6, is established.

[0165] The marking part 7 (Conjugal pad) comprises a marking area 8, distinct from the first and second superposition areas, where a marker conjugated to a ligand specific to S. aureus is deposited. In particular, it is a gold nanoparticle (AuNP) conjugated to an antibody directed against S. aureus.

[0166] During migration of the sample through the labeling zone 8, the labeled ligand, e.g. the anti-S. aureus antibody conjugated to the gold nanoparticle, binds to the S. aureus bacterium, thus forming a bacterium / labeled ligand complex. Said complex is then carried by the migration flow through the labeling part 7, then through the detection part 4.

[0167] The detection part 4 comprises a detection zone 5 distinct from the second and third superposition zones, where at least one phage specific to S. aureus or at least one protein of at least one phage specific to S. aureus is immobilized. The detection zone 5 is a line transverse to the strip 1, which can then be called “detection line” or “test line”.

[0168] Upon passage of the test line, the labeled bacteria / ligand complexes are immobilized by the specific recognition of S. aureus by the phage or the S. aureus-specific phage protein immobilized on the test line.

[0169] The presence of S. aureus is then revealed using the marker. The accumulation of AuNPs on the test line results in the appearance of a colored visual signal, particularly pink.

[0170] [Fig.8] illustrates an embodiment of a strip 1 for detecting S. aureus in a sample, comprising the following four parts: - a contact part 2 comprising a contact zone 3; - a marking portion 7 comprising a marking area 8 where an antibody directed against S. aureus can be deposited, labeled with a gold nanoparticle (AuNP) as a marker conjugated to a ligand specific to S. aureus; - a detection part 4 comprising a detection zone 5 of S. aureus, where at least one bacteriophage specific to S. aureus or at least one protein of at least one bacteriophage specific to S. aureus can be immobilized, - an absorbent part 6.

[0171] [Fig. 12] illustrates an embodiment of the detection with a strip 1 comprising four parts.

[0172] Optionally, the strip 1 comprises a system for controlling the migration of the sample from the contact part 2 to the detection part 4. For this, a first labeled ligand not specific to the bacteria of interest, i.e. which has no affinity for the bacteria of interest, such as a labeled primary antibody, is deposited on the labeling part 7 and / or is previously added to the sample, and the detection part 4 comprises a control zone 9, distinct from the detection zone 5, where a second ligand is immobilized which is specific to the first labeled ligand, such as a secondary antibody.

[0173] In particular, this control zone 9 is a line transverse to the strip 1, thus forming a control line or control line. In particular, the control zone 9 is on the detection part 4, between the second and third superposition zones.

[0174] The first labeled ligand of the labeling part 7 will be carried by capillarity with the sample to the control line, where it is systematically immobilized by the specific recognition of the second ligand immobilized on the control line.

[0175] The presence of the first ligand on the test line is then revealed using the marker. The appearance of the signal along the control line makes it possible to ensure that migration through the membrane has taken place correctly. The appearance of this signal on the control line is independent of the presence of the bacteria of interest in the sample tested. In particular, the marker is an AuNP.

[0176] Thus, in a strip 1 comprising such a control system, a positive analysis of the presence of the analyte of interest in the sample is characterized by the appearance of two visual signals, one on the test line and the other on the control line. Conversely, the absence of analyte of interest in the sample is characterized by the appearance of a single visual signal on the control line.

[0177] In one embodiment of the detection system, the first labeled ligand deposited on the labeling area 8 is a chicken antibody coupled to an AuNP, and the second ligand immobilized on the control line is an anti-chicken antibody.

[0178] [Fig. 9] illustrates an embodiment of the strip 1 comprising four parts and a control system. [Fig. 10] illustrates an embodiment of the detection with a strip 1 comprising four parts and a control zone 9.

[0179] 3.2. Evaluation of an LFA device with phages or phage proteins

[0180] LFA strips 1 for detecting S. aureus as described in section 3.1 were made, without a control system, by immobilizing on the detection zone 5 (test line) as S. aureus-specific bacteriophage: - phage 2 (CNCM 1-5408), - phage 3 (CNCM 1-5409), - phage 7 (CNCM 1-5410), or - phages 2, 3 and 7, or by immobilizing on the detection zone 5 as a bacteriophage protein specific to S. aureus: - a phage 2 RBP protein (SEQ ID NO: 1), - a phage 3 RBP protein (SEQ ID NO: 2), - a phage 7 RBP protein (SEQ ID NO: 3), or - the RBP proteins SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3 respectively of each of phages 2, 3 and 7.

[0181] Phages were deposited on detection zone 5 at a concentration of 1010 CFU / mL. Proteins were deposited on detection zone 5 at a concentration of 0.5 mg / mL.

[0182] For each strip 1, the anti-S. aureus antibody, Staphylococcus aureus Rabbit Polyclonal Antibody supplied by Thermofisher (Ref. 11578351), conjugated to gold nanoparticles, was impregnated on the marking area 8.

[0183] These 8 embodiments of strip 1 were tested for the detection of 19 strains of S. aureus in PBS buffer samples artificially infected with 107 CFU / mL of bacteria. Tests with PBS samples infected with 106 CFU / mL were also carried out.

[0184] To assess specificity, the 8 embodiments of strip 1 were also tested on PBS samples infected separately with other Staphylococcus species (Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus algentis) at concentrations of 107CFU / mL.

[0185] [Fig. 11] shows the results obtained for the detection of S. aureus strain 79 at 107 CFU / mL in a PBS sample, with LFA strips 1 where phage 2, 3 or 7, or where an RBP of phage 2 (SEQ ID NO: 1), an RBP of phage 3 (SEQ ID NO: 2) or an RBP of phage 7 (SEQ ID NO: 3), were immobilized on the test line.

[0186] When the sample does not contain bacteria (control) ([Fig. 11] - side A) no signal is observed on the test line. When the sample contains bacteria, a pink color signal is observed along the test line where said phages or said proteins of said phages have been immobilized ([Fig. 11] - side B).

[0187] Table 2 shows the results obtained for each strip 1 tested against each sample. A positive test for the detection of the bacteria is characterized by the appearance of the pink signal indicated "S" for "signal" in the table. A negative test is indicated by the sign " / ".

[0188] [Tables2] Bscisrîëb î Phage 1 Phage | Phage 1 Mem phages Souches 2 3 7 (2 / 3 / 7J Protéine phage 2 Protéine phage 3 Protéine phage 7 Mix Protéines <2 / 3,7) S.aüreys 73 e ! s I s ! s 8888^:8888 8888^:888= S BiiOiiii SlSfü' / i&b’S 81 | S | S | S | S S .3 s S.cîL'æL’S C24.b | S | S S s S Ft.a | S | S St s $ s S L5.a j / | / s S QtZ.b | | S St s $ s s S QU.b 1 < | [ S | S s s USa.a | S | I I S S s 13 F2.a 1 J | ; | S S.SLï'ôUS Ll.a | S | s | s s s 88::::::::::^:::::8:::::::: S.aarej / s G6.b llïïllïita llOli® b- S .aureus a । ;‘ I > 3 f 7 1 ' S.aüreus S I 5 â s S.awei / s 1 Da2 IIM । S 11™ 8888::S:8888 ■S aureus Z12c2b | S ] S.aurei / s 5S.d i । ] ' [ S .aureus SL.a [ S |__j| S Moqueuse | , | | ; | s'' s s $88^^ ||||^|||§ 8888j:jS^ | 53% | 37% | 83% | 88% 79% 79% 79% 84% Streptococeus uheris 2Eb '' ' S. sapraphy Scus_ suhsp.bovis E2V-B Schromogenes L15C / / ' 7 i S..haemcfySeus L7A / -f / 7 S.agnetïs L2tc ' / i S. epittermidîs L5C | / 1 / | 7 [£. S sgoai | no sign! detects

[0189] The results in Table 2 show that a LFA strip 1 comprising one of phages 2, 3 or 7 or these three phages, or comprising a protein from one of these three phages or a mixture of these three proteins, is very specific for detecting the presence of the S. aureus bacterium in a sample.

[0190] The results in [Fig. 11] and Table 2 therefore validate the use of whole S. aureus-specific phages or S. aureus-specific phage proteins, particularly RBPs, in an LFA strip 1 to detect the presence of S. aureus in a sample.

[0191] 3.3. Pre-treatment of the sample

[0192] A pre-treatment of the sample consisting of the addition of a surfactant was tested.

[0193] For this, 0.5% to 12% (w / v) Tween 20 was added to PBS buffer samples infected with S. aureus strain 79. These samples were then tested on a LFA strip 1 described above comprising phage 2 or RBP protein of phage 2 (SEQ ID NO: 1) immobilized on the test line.

[0194] The results show that a sample comprising from 0.5% to 12% (w / v) of surfactant makes it possible to obtain a more intense detection signal (results not shown).

[0195] Example 4: Another embodiment of the LFA device with phages or phage proteins

[0196] An alternative embodiment of the LFA device is an LFA strip 1 for detecting S. aureus, as described in Example 3, wherein: - on the marking zone 8, instead of depositing a marker conjugated to an anti-S. aureus antibody, it is a marker conjugated to at least one phage specific to S. aureus or to at least one protein of at least one phage specific to S. aureus, and - on detection zone 5, in particular on the test line, instead of immobilizing at least one phage specific to S. aureus or at least one protein of at least one phage specific to S. aureus, it is an antibody directed against S. aureus.

[0197] In this alternative embodiment, the LFA strip 1 for detecting S. aureus in a sample comprises in order the following four parts: - a contact part 2 comprising a contact zone 3 with the sample; - a marking part 7 comprising a marking zone 8 where a marker conjugated to at least one phage specific to S. aureus or a marker conjugated to at least one phage protein specific to S. aureus is deposited, - a detection part 4 comprising a detection zone 5 of S. aureus, where an anti-S. aureus antibody is immobilized, - an absorbent part 6.

[0198] The marking zone 8 may contain a marker conjugated to phage 2 (CNM I-5408), a marker conjugated to phage 3 (CNCM I-5409) or a marker conjugated to phage 7 (CNCM I-5410) or these three conjugated markers. It may also contain a marker conjugated to a protein of phage 2, a marker conjugated to a protein of phage 3, a marker conjugated to a protein of phage 7 or these three conjugated markers. In particular, the marker is a gold nanoparticle. In particular, said protein of phage 2 is the protein SEQ ID NO: 1, said protein of phage 3 is the protein SEQ ID NO: 2, said protein of phage 7 is the protein SEQ ID NO: 3.

[0199] Example 5: Another embodiment of the LFA device with phages or phage proteins - absence of labeling part

[0200] An alternative embodiment of the LFA device is an LFA strip 1 for detecting S. aureus as described in Example 3 in which the labeling portion 7, where a labeled ligand specific to the bacteria, such as an anti-S. aureus antibody, is deposited, is absent. Indeed, in this embodiment, the sample is previously placed in the presence of the label conjugated to a ligand specific to the bacteria, before bringing the sample into contact with the strip 1.

[0201] In this alternative embodiment, the strip 1 for detecting S. aureus in a sample, comprises in order the following three parts: - a contact part 2 comprising a contact zone 3 with the sample; - a detection part 4 comprising a detection zone 5 of S. aureus, where at least one bacteriophage specific to S. aureus or at least one protein of at least one bacteriophage specific to S. aureus is immobilized, - an absorbent part 6.

[0202] The detection zone 5 may contain a phage 2 (CNM 1-5408), a phage 3 (CNCM 1-5409) or a phage 7 (CNCM 1-5410) or these three phages. It may also contain a protein of phage 2, such as the protein SEQ ID NO: 1, a protein of phage 3 such as the protein SEQ ID NO: 2, a protein of phage 7 such as the protein SEQ ID NO: 3, or these three proteins.

[0203] Using this alternative embodiment of strip 1, the sample is first brought into contact with a label conjugated to a specific S. aureus ligand, to form labeled bacteria / ligand complexes in the sample.

[0204] After labeling, when the sample is brought into contact with the contact zone 3 of the strip 1, the complexes will migrate through the contact part 2 by capillarity, then through the detection part 4, to the detection zone 5, in particular a test line, where at least one phage specific to S. aureus or at least one protein of at least one phage of S. aureus is immobilized.

[0205] [Fig.6] illustrates a strip 1 comprising three parts. [Fig.7] illustrates a strip 1 comprising three parts in which the detection part 4 comprises a control zone 9.

[0206] Using this alternative strip 1, a first embodiment of the method for detecting the bacteria is a method in which the marker conjugated to a specific S. aureus ligand, with which the sample is previously brought into contact, is a marker conjugated to an antibody directed against S. aureus.

[0207] [Fig. 13] illustrates this alternative embodiment.

[0208] Using this alternative strip 1, a second embodiment of the method for detecting the bacteria is a method in which the marker conjugated to a specific S. aureus ligand, with which the sample is previously brought into contact, is a marker conjugated to at least one S. aureus-specific phage or a marker conjugated to at least one protein of at least one S. aureus-specific phage.

[0209] In particular, it is a marker conjugated to phage 2 (CNM 1-5408), a marker conjugated to phage 3 (CNCM 1-5409), a marker conjugated to phage 7 (CNCM 1-5410) or a mixture of these three markers conjugated to phages. In particular, it is a marker conjugated to a phage 2 protein, a marker conjugated to a phage 3 protein, a marker conjugated to a phage 7 protein or a mixture of these three markers conjugated to proteins. In particular, said phage 2 protein is the protein SEQ ID NO: 1, said phage 3 protein is the protein SEQ ID NO: 2, said phage 7 protein is the protein SEQ ID NO: 3.

[0210] Using this alternative strip 1, a third embodiment of the method for detecting the bacteria is a method in which the marker conjugated to a specific S. aureus ligand, with which the sample is previously brought into contact, is a marker conjugated to an anti-S. aureus antibody coupled to at least one S. aureus-specific phage, or a marker conjugated to an anti-S. aureus antibody coupled to at least one protein of a S. aureus-specific phage. The coupling is carried out by Ca2+ ions. [Fig.14] illustrates this third embodiment of the method.

[0211] In particular, it is a marker conjugated to an anti-S. aureus antibody coupled to phage 2 (CNCM 1-5408), a marker conjugated to an anti-S. aureus antibody coupled to phage 3 (CNCM 1-5409), a marker conjugated to an anti-S. aureus antibody coupled to phage 7 (CNCM 1-5410) or a mixture of these three markers conjugated to phages. In particular, it is a marker conjugated to an anti-S. aureus antibody coupled to a phage 2 protein (CNCM I-5408), a marker conjugated to an anti-S. aureus antibody coupled to a phage 3 protein (CNCM I-5409), a marker conjugated to an anti-S. aureus antibody coupled to a phage 7 protein (CNCM I-5410) or a mixture of these three markers conjugated to phage proteins. In particular, said phage 2 protein is the protein SEQ ID NO: 1, said phage 3 protein is the protein SEQ ID NO: 2, said phage 7 protein is the protein SEQ ID NO: 3.

[0212] When the marker is an AuNP, the presence of the bacteria in the sample is highlighted by the appearance of a visual signal, in particular pink in color, along the test line.

[0213] Example 6: Another embodiment of the device by LFA with phages or phage proteins

[0214] An alternative embodiment of the device is an LFA strip 1 for detecting S. aureus, as described in Example 5, wherein: - on the detection zone 5 instead of immobilizing at least one phage specific to S. aureus or at least one protein of at least one phage specific to S. aureus, it is an antibody specific to S. aureus or an aptamer specific to S. aureus.

[0215] In this alternative embodiment, the LFA strip 1 for detecting S. aureus in a sample, comprises in order the following three parts: - a contact part 2 comprising a contact area 3 with the sample, - a detection part 4 comprising a detection area 5 of S. aureus, where is immobilized an S. aureus-specific antibody or an S. aureus-specific aptamer. - an absorbent part 6.

[0216] Using this strip 1, a first embodiment of the method for detecting S. aureus is a method in which the sample is previously brought into contact with a marker conjugated to a phage specific to S. aureus, or with a marker conjugated to a protein of a phage specific to S. aureus, to form in the sample complexes bacteria / labeled phage or bacteria / labeled protein.

[0217] In particular, it is a marker conjugated to the CNCM 1-5408 phage, a marker conjugated to the CNCM 1-5409 phage, and / or a marker conjugated to the CNCM 1-5410 phage. More particularly, it is a marker conjugated to the CNCM 1-5408 phage, a marker conjugated to the CNCM 1-5409 phage and a marker conjugated to the CNCM 1-5410 phage. Even more particularly, said marker conjugated to these phages is a gold nanoparticle.

[0218] In particular, it is a marker conjugated to at least one protein of the phage CNCM 1-5408, a marker conjugated to at least one protein of the phage CNCM 1-5409, and / or a marker conjugated to at least one protein of the phage CNCM 1-5410. More particularly, it is a marker conjugated to at least one protein of the phage CNCM 1-5408, a marker conjugated to at least one protein of the phage CNCM 1-5409 and a marker conjugated to at least one protein of the phage CNCM 1-5410. In particular, said at least one protein is an RBP. In particular, said phage 2 protein is protein SEQ ID NO: 1, said phage 3 protein is protein SEQ ID NO: 2, said phage 7 protein is protein SEQ ID NO: 3. More particularly, said phage protein-conjugated marker is a gold nanoparticle.

[0219] Using this strip 1, a second embodiment of the method for detecting the bacteria is a method in which the sample is previously brought into contact with a marker conjugated to a phage specific to S. aureus coupled to a labeled anti-S. aureus antibody, a marker conjugated to an anti-S. aureus antibody coupled to a phage specific to S. aureus, a marker conjugated to a protein of a phage specific to S. aureus coupled to an anti-S. aureus antibody or a marker conjugated to an anti-S. aureus antibody coupled to a protein of a phage specific to S. aureus.

[0220] In particular, it is a marker conjugated to the CNCM 1-5408 phage coupled to an anti-S. aureus antibody, a marker conjugated to the CNCM 1-5409 phage coupled to an anti-S. aureus antibody and / or a marker conjugated to the CNCM 1-5410 phage coupled to an anti-S. aureus antibody. In particular, it is a marker conjugated to a CNCM 1-5408 phage protein coupled to an anti-S. aureus antibody, a marker conjugated to a CNCM 1-5409 phage protein coupled to an anti-S. aureus antibody and / or a marker conjugated to a protein of the CNCM 1-5410 phage coupled to an anti-S. aureus antibody. In particular, it is a marker conjugated to an anti-S. aureus antibody coupled to the CNCM 1-5408 phage, a marker conjugated to an anti-S. aureus antibody coupled to the CNCM 1-5409 phage and / or a marker conjugated to an anti-S. aureus antibody coupled to the CNCM 1-5410 phage. In particular, it is a marker conjugated to an anti-S. aureus antibody coupled to a protein of the phage CNCM 1-5408, a marker conjugated to an anti-S. aureus antibody coupled to a protein of the phage CNCM 1-5409 and / or a marker conjugated to an anti-S. aureus antibody coupled to a protein of the phage CNCM 1-5410. In particular, said protein of phage 2 (CNCM 1-5408) is the protein SEQ ID NO: 1, said protein of phage 3 (CNCM 1-5409) is the protein SEQ ID NO: 2, said protein of phage 7 (CNCM I-5410) is the protein SEQ ID NO: 3.

[0221] Bacteria / phage-labeled antibody, bacteria / antibody-labeled phage, bacteria / phage protein-antibody or bacteria / antibody-labeled phage protein complexes are then formed in the sample.

[0222] In particular, for these two embodiments of the detection method, AuNPs are used as a marker and the presence of the bacteria in the sample is revealed by the appearance of a colored signal, in particular pink, in the detection zone 5, in particular along the test line.

[0223] Example 7: Another embodiment of the LFA device with phages or phage proteins

[0224] A particular embodiment of the LFA device is a strip 1 as described in Example 3, in which: - on the labeling zone 8, instead of a label conjugated to an anti-S. aureus antibody, the labeled S. aureus-specific ligand is a label conjugated to a S. aureus-specific phage or a label conjugated to a protein of a S. aureus-specific phage.

[0225] In this particular embodiment, the strip 1 for detecting a bacterium of interest in a sample comprises, in order, the following four parts: - a contact part 2 comprising a contact zone 3 with the sample to be tested - a marking part 7 comprising a marking zone 8 where at least one marker conjugated to a phage specific to S. aureus or at least one marker conjugated to a protein of a phage specific to S. aureus is deposited, - a detection part 4 comprising a detection zone 5 of S. aureus, where at least one phage specific to S. aureus and / or at least one protein of a phage specific to S. aureus is immobilized, - an absorbent part 6.

[0226] The labeling portion 7 may comprise a label conjugated to phage CNCM I-5408, a label conjugated to phage CNCM I-5409 and / or a label conjugated to phage CNCM I-5410. In particular, it may comprise a mixture of these three labels conjugated to phages. The labeling portion 7 may comprise a label conjugated to a protein of phage CNCM I-5408, a label conjugated to a protein of phage CNCM I-5409 and / or a label conjugated to a protein of phage CNCM I-5410. In particular, said phage 2 protein (CNCM 1-5408) is protein SEQ ID NO: 1, said phage 3 protein (CNCM 1-5409) is protein SEQ ID NO: 2, said phage 7 protein (CNCM 1-5410) is protein SEQ ID NO: 3. In particular, it may comprise a mixture of these three markers conjugated to phage proteins.

[0227] In particular, AuNPs are used as a marker and the presence of the bacteria in the sample is revealed by the appearance of a colored signal, in particular pink, in the detection zone 5, in particular along the test line. Reference to deposited biological material

[0228] In the present application, reference is made to the following bacteriophage strains, all deposited with the CNCM on March 21, 2019 by Vetophage SAS: - phage 2, identification reference with the CNCM “Vetophage - phi 2”, whose registration number is “1-5408”; - phage 3, identification reference with the CNCM “Vetophage - phi 3”, whose registration number is “1-5409”; - phage 7, identification reference with the CNCM “Vetophage - phi 7”, whose registration number is “1-5410”.

[0229] In the present application, reference is made to the following bacteriophage strains, all deposited with the CNCM on February 12, 2020 by Vetophage SAS: - Reference phage for identification with the CNCM “phi 9”, whose registration number is “1-5491”; - Reference phage for identification with the CNCM “phi 10”, whose registration number is “1-5492”. List of cited documents

[0230] For all useful purposes, the following publications are cited in the present application: - Reinoso et al., RAPD-PCR analysis of Staphylococcus aureus strains isolated from bovine and human hosts. Microbiological Research, Volume 159, Issue 3, September 2004, pages 245-255; - Foster Timothy J., Antibiotic resistance in Staphylococcus aureus. Current status and future prospects. FEMS Microbiology Review, Volume 41, Issue 3, May 2017, pages 430-449. - Nanerjee and Jaiswal., Recent Advances in Nanoparticle-Based Lateral Flow Im-munoassay as a Point-Of-Care Diagnostic Tool for Infections Agents and Diseases (Ruptanu Banerjee and Amit Jaiswal), 2018 143(9):1970-1996. - Sajid and a / . Designs, formats and applications of lateral flow assay: A literature review. Journal of Saudi Chemical Society, 2015, 19, 689-705. - Patent EP1086372B1. Collection device for single assay or oral fluids. Filed on March 29, 1999 and issued on May 31, 2006. - US Patent 8,399,261 B2. Lateral flow assay system and methods for its use. Issued from PCT / US2008 / 0686821 filed on June 27, 2008. - International application WO 2017 / 072078, Subtractive immunoassay method and lateral flow immunochromatography assay strip for performing the method. Filed on October 24, 2016.

Claims

Claims

1. A lateral flow chromatography strip (1) for detecting Staphylococcus aureus in a sample, characterized in that it comprises at least one part which comprises at least one bacteriophage specific for S. aureus and / or at least one binding protein (RBP) of a bacteriophage specific for S. aureus.

2. Strip (1) according to claim 1, characterized in that it comprises in order at least: - a contact part (2) comprising a contact zone (3) with the sample, - a detection part (4) comprising a detection zone (5) of S. aureus which comprises at least one bacteriophage specific to S. aureus and / or at least one RBP protein of a bacteriophage specific to S. aureus, - an absorbent part (6).

3. Strip (1) according to claim 2, characterized in that it further comprises between the contact part (2) and the detection part (4), a marking part (7) which comprises a marking area (8).

4. Strip (1) according to claim 1 or 3, characterized in that it comprises at least: - a contact part (2) comprising a contact zone (3) with the sample; - a marking part (7) comprising a marking zone (8) which comprises a marker, - a detection part (4) comprising a detection zone (5) of S. aureus which comprises at least one bacteriophage specific for S. aureus and / or at least one RBP protein of at least one bacteriophage specific for S. aureus, - an absorbent part (6).

5. Strip (1) according to claim 1, characterized in that it comprises at least: - a contact part (2) comprising a contact zone (3) with the sample; - a marking part (7) comprising a marking zone (8) which comprises a marker conjugated to at least one ligand specific for S. aureus chosen from at least one bacteriophage specific for S. aureus and at least one RBP protein of at least one specific bacteriophage of S. aureus; - a detection part (4) comprising a detection zone (5) of S. aureus which comprises at least one ligand specific for S. aureus; - an absorbent part (6), said at least one ligand specific for S. aureus is at least one antibody directed against S. aureus, at least one aptamer specific for S. aureus, at least one bacteriophage specific for S. aureus or at least one RBP protein of at least one bacteriophage specific for S. aureus.

6. Strip (1) according to one of claims 1 to 5, characterized in that said at least one bacteriophage specific for S. aureus is chosen from bacteriophage CNCM 1-5408, bacteriophage CNCM 1-5409, bacteriophage CNCM 1-5410, bacteriophage CNCM 1-5491 and / or bacteriophage CNCM 1-5492, and said at least one RBP protein of at least one bacteriophage specific for S. aureus is chosen from at least one RBP protein of bacteriophage CNCM 1-5408, at least one RBP protein of bacteriophage CNCM 1-5409, at least one RBP protein of bacteriophage CNCM 1-5410, at least one RBP protein of bacteriophage CNCM 1-5491 and / or at least one RBP protein of bacteriophage CNCM 1-5492.

7. Strip (1) according to claim 6, characterized in that said at least one RBP protein of the bacteriophage CNCM 1-5408 is the protein SEQ ID NO: 1, said at least one RBP protein of the bacteriophage CNCM 1-5409 is the protein SEQ ID NO: 2, and said at least one RBP protein of the bacteriophage CNCM 1-5410 is the protein SEQ ID NO:

3.

8. Method for detecting S. aureus in a sample characterized in that it comprises: - a step of marking the bacteria or S. aureus in the sample; - a step of bringing the sample into contact with the contact zone (3) of a strip (1) according to one of claims 2 to 7; - a step of detecting the marker on the detection zone; - a step of analyzing the presence or absence of S. aureus in the sample.

9. Method for detecting S. aureus in a sample characterized in that it comprises: - a step of bringing the sample into contact with the contact zone (3) of a strip (1) according to one of claims 3 to 7; - a step of detecting the marker on the detection zone; - a step of analyzing the presence or absence of S. aureus in the sample.

10. Kit for detecting S. aureus in a sample characterized in that it comprises: - a strip (1) according to one of claims 1 to 7, - a container intended to receive the sample, - a container comprising a marker.

11. Kit for detecting S. aureus, in a sample, characterized in that it comprises: - a strip (1) according to one of claims 3 to 7, - a container intended to receive the sample.

12. Use of at least one bacteriophage specific for S. aureus and / or at least one RBP protein of at least one bacteriophage specific for S. aureus, for detecting S. aureus in a sample, characterized in that said at least one bacteriophage specific for S. aureus and / or said at least one protein of a bacteriophage specific for S. aureus are used in a lateral flow chromatography strip (1) according to one of claims 1 to 7.

13. Use according to claim 12, characterized in that said at least one bacteriophage specific for S. aureus is bacteriophage CNCM I-5408, bacteriophage CNCM I-5409, bacteriophage CNCM I-5410, bacteriophage CNCM I-5491 and / or bacteriophage CNCM I-5492, and / or characterized in that said at least one RBP protein of at least one bacteriophage specific for S. aureus is at least one RBP protein of phage CNCM I-5408, at least one RBP protein of bacteriophage CNCM I-5409, at least one RBP protein of bacteriophage CNCM I-5410, at least one RBP protein of bacteriophage CNCM I-5491 and / or at least one RBP protein of bacteriophage CNCM 1-5492.

14. Use according to claim 13, characterized in that said at least one RBP protein of bacteriophage CNCM 1-5408 is the protein SEQ ID NO: 1, said at least one RBP protein of bacteriophage CNCM 1-5409 is the protein SEQ ID NO: 2, and said at least one RBP protein of bacteriophage CNCM 1-5410 is the protein SEQ ID NO: 3.